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IV. Summary 
 
Myeloid-derived suppressor cells (MDSCs) are a heterogeneous cell group, which 
share close phenotypical similarities with conventional myeloid cells. In contrast to 
conventional myeloid cells, MDSCs have the ability to suppress other immune cells. 
MDSCs have been reported to suppress dendritic cells (DCs), natural killer (NK) and 
natural killer T cells (NKT) cells. However, the “gold standard” to characterize and 
discriminate them from other myeloid cells is the ability to suppress T-cell function. 
MDSCs apply multiple mechanisms of suppression, including production of reactive 
oxygen and nitrogen species, arginase-1 and production of several immunomodulatory 
cytokines. MDSCs have been described to arise in several forms of cancer, where they 
correlate with poor prognosis. Beyond cancer, MDSCs have been involved in chronic 
inflammatory and autoimmune diseases. However, in these situations the effects of 
MDSCs are still controversial and need further investigation. B cells are the key players 
of the humoral adaptive immune response. Their main function is to produce 
antibodies. B cells are involved in eliminating mainly extracellular invasive pathogens. 
Moreover, they are important modulators of several diseases, such as systemic lupus 
erythematous and rheumatoid arthritis, where autoantibodies lead to the development 
of chronic inflammation and loss of tissue function. MDSCs suppress T cells and other 
immune cells functions, but their ability to modulate B-cell responses is still poorly 
understood. The aim of this study is to study interactions between human 
polymorphonuclear-MDSCs (PMN-MDSCs) and B cells. For that purpose, we 
performed B-cell proliferation assays by co-culturing activated B-cell with PMN-
MDSCs. The data was then assessed by flow cytometry, image stream, and ELISA. 
Our studies demonstrate that human PMN-MDCs differentially modulate B-cell function 
by suppressing B-cell proliferation and antibody production in a stimulus- and dose-
dependent fashion. We further demonstrate that this MDSC-mediated effect is cell-
contact dependent and involves established mediators such as arginase-1, nitric oxide 
(NO), reactive oxygen species (ROS) as well as B-cell death. Collectively, our studies 
provide novel evidence that human MDSCs modulate B cells, which could have future 
implications for immunotherapy approaches. 
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V. Zusammenfassung 
 
Myeloische Suppressorzellen (MDSCs) sind eine heterogene Zellpopulation, die 
konventionellen myeloischen Zellen phenotypisch ähnlich sind. Im Vergleich zu 
konventionellen myeloischen Zellen haben sie die Fähigkeit andere Immunzellen zu 
supprimieren, insbesondere T-Zellen. MDSCs haben mehrere 
Suppressionsmechanismen zu denen unter anderem die Produktion von reaktiven 
Sauerstoff- und Stickstoffspezies, Arginase 1 sowie diverse immunmodulatorische 
Zytokine zählen. MDSCs akkumulieren in Tumorpatienten, bei denen sie mit einer 
schlechteren Prognose im Zusammenhang stehen. Sie spielen nicht nur bei 
Tumorerkrankungen, sondern auch bei chronisch inflammatorischen Erkrankungen 
und Autoimmunerkrankungen eine Rolle. Die pathophysiologische Relevanz von 
MDSCs bei diesen Erkrankungen ist bislang allerdings noch unzureichend verstanden. 
B-Zellen sind wichtige Immunzellen der humoral adaptiven Immunantwort, da ihre 
Hauptaufgabe darin besteht, Antikörper zu produzieren. Sie sind hauptsächlich für die 
Eliminierung von extrazellulären Pathogenen zuständig. B-Zellen sind zudem 
Hauptmodulatoren von diversen Krankheiten, wie systemischer Lupus Erythematodes 
und rheumatoider Arthritis, bei denen Autoantikörper zur Entwicklung von chronischen 
Entzündungsreaktionen und Gewebeschäden führen. MDSCs supprimieren T-Zellen 
und modulieren weitere Immunzellen. Eine mögliche Interaktion mit B-Zellen ist jedoch 
bislang kaum untersucht. Das Ziel dieser Studie war es, mögliche Interaktionen 
zwischen polymorphonukleären MDSCs (PMN-MDSCs) und B-Zellen zu untersuchen. 
Dazu führten wir B-Zell Proliferationsversuche durch, in denen wir aktivierte B-Zellen 
mit PMN-MDSCs ko-kultivierten. Die Daten wurden mittels Durchflusszytometrie, 
ImageStream und ELISA analysiert. Wir konnten zeigen, dass humane PMN-MDSCs 
B-Zellen differentiell modulieren, indem sie dosisabhängig die B-Zell Proliferation und 
die Antikörperproduktion  supprimieren. Wir konnten zudem demonstrieren, dass 
dieser Effekt abhängig von Zellkontakt ist und für PMN-MDSCs typische Mechanismen 
wie die Expression von Arginase-1, Stickstoffoxid und reaktive Sauerstoffspezies 
sowie auch B-Zelltod involviert sind. Zusammenfassend konnten wir neue 
Erkenntnisse gewinnen, dass humane MDSCs B-Zellen modulieren und somit neue 
potentielle Targets für Immuntherapien darstellen. 
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1. Introduction 
 
1.1The innate immune system 
  
The immune system defends the human body against several microorganisms such 
as, viruses, bacteria, fungi and parasites, which are commonly known as pathogens. 
It is also involved in the recognition and elimination of non-self-substances (antigens), 
which we are regularly exposed [1, 2]. By using a complex network of physical barriers 
(skin and mucosa), chemical compounds (defensins and complement proteins), 
tissues (bone marrow and blood), organs (thymus and spleen) and cells (leukocytes 
or white blood cells), the immune system constantly avoids the establishment of many 
infective microbes in our body [3, 4]. However, these invaders may cause infections 
and can be lethal when the immune system fails in eliminating them [5, 6].  
The immune responses are divided into two main categories, innate and  adaptive 
immune responses [7]. The innate immune response is the first line defense of our 
body, and its effects are immediately observed after the invasion of the human body 
by an antigen or pathogen. The innate immune system comprises the physical, 
chemical and cellular barriers of our body [8-10]. The skin and mucosa prevent the 
invasion of pathogens or allergens (antigens) physically [11, 12], accompanied by 
chemical components of the mucous, skin and tissue, such as defensins and proteins 
of the complement system. The former act as an antimicrobial and play important role 
to eliminate the unwanted invader. The latter is a complex system of proteins that bind 
to pathogen`s cell wall and either lyse the pathogen or attract immune cells to eliminate  
it [13, 14].  
Microorganisms which pass the physical and chemical barriers of the immune system 
will then face the cellular defense mechanisms. Langerhans’s cells (Figure 1) are the 
macrophages that reside in the skin and the first cells to encounter a pathogen [15, 
16]. They recognize and phagocyte the invaders by using pattern recognition receptors 
(PRRs), which are involved in several signaling pathways, such as host cell activation 
and cytokines production. PRRs identify the pathogen-associated molecular patterns 
(PAMPs) present on microbes [10, 17, 18]. 
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Figure 1: Comparison between innate and adaptive immune system. In the left panel is depicted 
the nonspecific defense mechanisms of the innate immune response that come into play immediately 
after a pathogen invasion in the body. These mechanisms include physical barriers such as skin, 
chemicals with antimicrobial activities and cells such as macrophages, neutrophils, monocytes, mast 
cells, monocytes and NK cells. In the right panel is shown the mechanisms that comprise the adaptive 
immune system composed of highly specialized, systemic cell, such as lymphocytes T and B. They act 
in a very specific manner in order to eliminate pathogens and prevent the establishment of infections. 
Modified from Kumar et al. (2014) [9].  
Furthermore, macrophages can phagocyte the invader microbe forming the 
phagosome. The phagosome merges with cytoplasmic granules that contain 
digestives enzymes (lysozymes) and form the phagolysosome, which kills the 
pathogen. Macrophages are also involved in the production and release of reactive 
oxygen species (ROS) and nitrogen species, such as nitric oxide (NO), collectively 
responsible for the respiratory burst. These anionic chemical species are involved in 
the elimination of the pathogen, they also enhance the acidity intracellularly thus 
induce cell death [19-22]. In parallel, macrophages secrete pro-inflammatory 
cytokines, such as interferons, as well as chemokines contributing to the development 
of a complex network of cells and proteins with vasoactive and cell activation 
capacities, called inflammation [23]. The inflammatory process happens in order to 
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eliminate the invader and heal the injury. The physical signs of inflammation are 
redness, heat, pain and tumor [24]. 
  
 
 
 
 
 
 
 
 
 
 
 
Figure 2: Development of myeloid and lymphoid cells in the bone marrow. Homeostatic 
myelopoiesis and lymphopoiesis both originated from the hematopoietic stem cell (HSC) in the bone 
marrow. In parallel, it is depicted the changes caused by excessive amount of soluble and non-soluble 
factors in the tumor and inflammed microenvironment and in infections, contributing to the abnormal 
differentiation of immature myeloid cells (IMCs) leading to the appearance, expansion and accumulation 
of MDSCs (abnormal myelopoiesis). Adapted from Gabrilovich and Nagaraj (2009) [25]. 
After macrophages, neutrophils [26, 27] and monocytes [28] enter the tissues (Figure 
1). They leave the peripheral blood attracted by chemokines, such as CC motif ligand 
2 (CCL2), interleukin 8 (IL-8) released by the cells in the inflamed environment as well 
as due to the enhanced permeability of the blood vessels due to cytokine activity. The 
neutrophils act similarly to macrophages, they phagocyte and kill invading microbes 
also by means of digestive enzymes from their different types of granules, they also 
are involved in the respiratory burst and production of cytokines [29, 30].  
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Natural killer cells (NK cells) and mast cells are also innate cells. The former play 
important roles in the immune responses, for instance, eliminating intracellular 
pathogens and producing INF-γ and the latter are key effector in allergic reactions [31-
34]. 
Dendritic cells (DCs) are the link between the innate and adaptive responses, they 
sense, uptake, process and present antigens to T cells in secondary lymphoid organs 
(spleen and lymph nodes) thereby initializing the adaptive immune response [35].  
T cells and B cells are the effector cell types of the adaptive immune response. While 
T cells act as helper cells by activating other immune cells (T CD4+) or mediating direct 
cytotoxicity to infected cells (T CD8+), B cells produce highly specific antibodies. The 
adaptive immune response may take hours or days after the initial pathogen invasion 
to begin its defensive mechanisms [36]. It is highly specific against recognized antigens 
such as proteins, lipids, carbohydrates or nucleic acids of pathogens [37, 38]. After 
eliminating the harmful agent, the adaptive immune response develops memory cells, 
which remembers encountered pathogens and upon a re-encounter, they respond in 
a faster and stronger way [39-41].   
1.2 Myeloid-derived suppressor cells 
 
1.2.1 Definition, origin, generation and expansion  
 
The immunosuppressive activities of myeloid cells were firstly appreciated, almost forty 
years ago, when Bennet et al. (1978) [42] observed that Bacillus Calmette-Guérin 
(BCG) enhanced the suppressive activity of bone marrow cells, by inhibiting the 
development of cell-mediated immunity. Nowadays it is known that these cells arise 
and accumulate from an abnormal hematopoiesis, and due to changes in the cellular 
microenvironment caused by the presence of tumors and excessive colony-stimulating 
activity. [43, 44]. Consistent investigations have been performed in order to compile 
evidences about the generation of these immune-suppressive cells, as well as to 
characterize them, phenotypically, morphologically and functionally. It is now known 
that some cells subsets from lymphoid and myeloid origin can suppress the immune 
system, under both pathological and physiological conditions.  Regulatory T and B cells 
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(Tregs and Bregs), tumor-associated macrophages (TAMs), dendritic cells (DCs), 
mesenchymal stromal cells and myeloid-derived suppressor cells (MDSCs), comprise 
the main cell types involved in this phenomenon [45-50]. 
Myeloid-derived suppressor cells (MDSCs) are described as an immature and 
heterogeneous cell population, arising from an abnormal differentiation of the immature 
myeloid cells (IMCs) in the bone marrow (Figure 2). In cancer, MDSCs have been 
described to positively correlate with bad prognosis of patients, induction of 
angiogenesis, tumor progression and metastasis [25, 50]. 
Several tumor and inflammatory cell-derived factors induce the generation and 
accumulation of MDSCs [51]. The altered cellular microenvironment, with a persistent 
production of cytokines and chemokines lead to the expansion and activation of 
MDSCs. Cytokines such as stem cell factor (SCF), granulocyte-macrophage colony-
stimulating factor (GM-CSF), macrophage colony-stimulating factor (M-CSF), 
interleukin (IL)-13, IL-10, vascular endothelial growth factor (VEGF) and chemokines 
such as, CCL2 or monocyte chemoattractant protein-1 (MCP-1), C-X-C motif 
chemokine 12 (CXCL12) and CXCL18 (IL-8) and other factors, such as prostaglandin 
E2 (PGE2) are also important players in the induction of MDSCs (Figure 2) [25, 50-56]. 
1.2.2 Characterization of human myeloid-derived suppressor cells 
 
1.2.2.1 Phenotypically 
 
MDSCs comprise a heterogeneous group of myeloid cells and that makes it difficult to 
phenotypically identify them. In humans, two subtypes of MDSCs have been 
described, granulocytic or polymorphonuclear MDSCs (PMN-MDSCs) and monocytic 
MDSCs (M-MDSCs). Human PMN-MDSCs are characterized according their surface 
markers as CD11b+CD14-CD15+CD66b+ and M-MDSCs as CD11b+CD14+HLA-DR-
/lowCD15-. The general phenotypic features of MDSCs can be discriminate in the early 
stage of these cells (eMDSC), as lineage negative or Lin- (CD3, CD14, CD56, CD15, 
and CD19), HLD-DR- and CD33+ (Table 1). Between CD33 and CD11b either one or 
both can be used as a myeloid marker [55, 57].  
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Table 1: Human MDSC subtypes and surface markers for phenotyping identification 
MDSC subtype Surface markers 
PMN-MDSC CD11b+CD14-CD15+ (or CD66b+) 
M-MDSC CD11b+CD14+HLA-DR-/lowCD15-. 
eMDSC Lin- (CD3, 14, 56, 15 and 19), HLD-DR- CD33+ 
eMDSC: early-stage myeloid-derived suppressor cell; M-MDSC: monocytic myeloid-derived suppressor cell; PMN-
MDSC: polymorphonuclear myeloid-derived suppressor cell.  
 
Due to the phonotypical similarities among MDSCs, neutrophils or monocytes, only the 
identification by receptor markers is not enough to distinguish them. It is necessary 
additional functional or suppressive assays. In addition, PMN-MDSCs can be 
separated from neutrophils by their gradient of centrifugation behavior. PMN-MDSCs 
after Ficoll density centrifugation dislocate to the low-density or peripheral blood 
mononuclear cell (PBMC) fraction, whereas the neutrophils move to the high-density 
fraction [25, 51, 55, 58, 59]. 
1.2.2.2 Functional and biochemical identification  
  
According to Bronte et al. (2016) [55], the “gold” standard to identify MDSCs is by 
verifying their suppressive activity towards  T cells [54, 60-62]. Therefore, the myeloid 
phenotypic description (Table 1) plus proliferative and functional assays involving co-
culture of T cells and MDSCs are sufficient information to characterize MDSCs. [55, 
63, 64]. 
Moreover, MDSCs can also be discriminated from other myeloid cells by biochemical 
and genetic markers. In this regard, it is important to observe that MDSCs compared 
to conventional myeloid cells have enhanced expression of NADPH oxidase (Nox2) 
thus they produce large amount of ROS [65]. In addition, they also show an increased 
expression of arginase-1 (arg1) [66]. High expression of nitric oxide synthase 2 (nos2) 
or inducible nitric oxide synthase (iNOS) has also been described in MDSCs. iNOS 
leads to increased production of nitric oxide (NO) [25, 67]. Furthermore, it is also 
observed higher activity of the transcription factors signal transducer and activator of 
transcription 1 and 3 (STAT1 and STAT3) as shown in Figure 3 [25, 55, 68]. All the 
above-mentioned factors are involved in the suppressive mechanisms of MDSCs [51]. 
The biochemical peculiarities maybe are the bottom line in distinguishing MDSCs from 
neutrophils and monocytes [55]. 
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1.2.2.3 Suppressive functions of myeloid-derived suppressor cells 
MDSCs use of multiple mechanisms to suppress the anti-tumor activity of other 
immune cells, and it may be due to their heterogeneity [25, 54, 69, 70] (Figure 3).  
According to Kumar et al. (2016) [51], these mechanisms are localization dependent 
(tumor or peripheral lymphoid organs) and include ROS, NO, arginase-1, indoleamine 
2,3-dioxygenase (IDO), suppressive cytokines (IL-10, Tumor growth factor-beta (TGF-
β)), tumor necrosis factor-alpha (TNF-α) and induction of immune-regulatory cells. 
Taking together the suppressive activities of MDSCs, they can be specific and non-
specific. [71-79]. 
Increased production of ROS (Figure 3) is a key characteristic of MDSCs, especially 
PMN-MDSCs. This mechanism is mediated by antigen-specific interaction with the 
target cell thus require cell-to-cell contact and can be induced by tumor 
microenvironment factors, such as IL-10, TGF-β, and GM-CSF. [25, 80-82]. ROS are 
strongly oxidative compounds that inhibit T-cell proliferation and function by inducing 
loss of CD3 ζ-chain [67, 69, 83]. The formation of ROS in myeloid cells is mediated by 
NADPH oxidase, which induces superoxide anion (O2-) formation [65, 69]. O2- strongly 
reacts with NO leading to the formation of peroxynitrite (ONOO-), capable of nitrating 
amino acids from the T-cell receptor (TCR), inducing T-cell anergy. In addition, ROS 
is also involved in T-cell apoptosis, inhibition of proliferation and nitration of many other 
T cell-related proteins [59, 80, 84]. 
Another important suppressive mechanism used by MDSCs is the deprivation of L-
arginine (Figure 3), which is substrate for arginase-1 and inducible nitric oxide 
synthase (iNOS). These two enzymes play important roles in the contact-independent 
suppression of  T-cell function and proliferation [66]. Arginase-1 catalyzes L-arginine 
into urea and L-ornithine and iNOS originates nitric oxide (NO) [25, 85, 86]. Excessive 
activity of arginase-1 deprives L-arginine in the tumor environment abrogating T-cell 
proliferation, also via decreasing CD3 ζ-chain and inducing cell cycle arrest [87]. NO 
induces T-cell apoptosis and it is involved in suppression mediated by inhibition of 
kinases and STATs [88]. NO is more involved in M-MDSCs modulatory actions and 
arginine-1 is used by both MDSCs subtypes [82] (Figure 3). 
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MDSCs can promote the de novo development of CD4+CD25+FOXP3+ regulatory T 
cells (Tregs) (Figure 3), as an indirect mechanism of suppression. Many mechanisms 
are suggested for MDSCs generation of Tregs such as presence of IL-10, and INF-γ 
in the cell environment and activation of tumor-specific T cells [89]; via expression of 
cytotoxic lymphocyte antigen 4 (CTLA-4), arginase-1 and antigen tumor presentation 
by MDSCs [78, 90]. Despite there are indications of the MDSCs involvement in Tregs 
generation, it is rather controversial once there are scientific finds showing the opposite 
or limited collaboration of MDSCs in this phenomenon, but these two 
immunoregulatory cell type might cross-talk in the cellular network of the immune 
response [91]. 
ROS, iNOs, arginase-1 inhibitors, such as diphenyleneiodonium (DPI), L-NG-
monomethyl Arginine citrate (L-NMMA), and Nω-Hydroxy-nor-L-arginine (nor-NOHA) 
respectively, are used to address the mechanisms applied by MDSCs to suppress 
immune functions [92]. 
Many other biological mechanisms seem to play roles in the MDSCs functions, such 
as indoleamine-pyrrole 2,3-dioxygenase (IDO) [93-95], suppressive cytokines, such as 
IL-10 and TGF-β [55, 96, 97], depletion of essential amino acids such as cysteine [51, 
98] and the S100 proteins, S100A8/9 [99]. All these mechanisms are involved in 
abrogating or decreasing T-cell immune functions and/or proliferation. It is important to 
notice that even though MDSCs apparently use of multiple mechanisms to exert their 
suppressive functions, not all of them happen simultaneously, but rather according to 
the different states of differentiation of these cells [51]. 
1.2.3 Myeloid-derived suppressor cells and diseases other than cancers 
 
Despite most of the investigations and the acquired knowledge regarding MDSCs 
come from studies in tumors [54, 98, 100], it is important to consider, that the 
appearance and accumulation of this immunosuppressive cell population is not 
restricted to tumors. Likewise, they have also been described in several other 
pathological conditions such as chronic inflammation, autoimmune diseases, 
infections, trauma, transplantation, sepsis, as well as in the steady-state. MDSCs play 
different roles in different pathologies, and their suppressive activities can be either 
  
22 
 
beneficial or detrimental. In addition, MDSCs can modulate the immune response to 
Th1 or Th2, generate Tregs and induce apoptosis in immune cells [67, 92, 101-109].  
 
Figure 3: Main mechanisms of suppression applied by MDSCs. Both PMN-MDSC and M-MDSCs 
are shown and their main mechanisms of immunosuppression are depicted, such as production of ROS, 
upregulation of arginase-1, production of NO and induction of Tregs. The main cytokines and 
transcription factors involved are also shown. These mechanisms activate MDSCs and are involved in 
the induction and accumulation of these suppressive cells in tumor and inflammatory 
microenvironments. Adapted from Gabrilovich and Nagaraj (2009) [25], Bodogai et al. (2015) [110], Yu 
et al. (2013) [93], Kumar et al. (2016) [51] and Srivastava et al. ( 2010) [111]. 
 
 
 
  
23 
 
1.2.4 Clinical implications of myeloid-derived suppressor cells 
 
A vast number of studies reveal that MDSCs can exert their suppressive activities on 
T, DCs, NK, NKT cells and monocytes [80, 112, 113]. B cells have been described to 
cross-talk with MDSCs  and experience their suppressive effects in several contexts 
such as HIV infection [114, 115], autoimmune disease [116] , tumor [110] and in the 
induction of regulatory B cells (Bregs) [117, 118]. 
MDSCs are known to inhibit T cells anti-tumor microenvironment immune responses, 
and to communicate in several ways with other immune cells, making then a complex 
web of cells cross-talking. This elevates the importance in targeting MDSCs and other 
myeloid suppressive cells in the clinical or therapeutic implications of tumor treatment. 
Table 2 shows a summary of some compounds which have been described for 
potential use to decrease MDSCs in the tumor microenvironment as well as their main 
mechanisms [98]. 
1.3 B cells  
 
1.3.1 Definition and development 
 
B cells were discovered about fifty years ago by Cooper and colleagues (1965) [119], 
by doing experiments with the “Bursa of Fabricius” from chickens, leading to the name 
B cells. They are the main immune cells involved in the humoral adaptive immune 
response, which is mediated by the secretion of antibodies. Antibodies are 
glycoproteins belonging to the immunoglobulin’s superfamily, they confer the first line 
protection mainly against extracellular pathogens, such as bacteria and microbial 
products [120-122]. B cells are involved in both, hemostasis [123] and pathological 
conditions such as autoimmune diseases, tumors, infections and hypersensitivity [124-
129].  
B cells have their primordial importance for reasons that involve the elimination of a 
body´s invaders by mounting a polyclonal antibody response [130], as well as providing 
one of the most powerful tools of the contemporary immunological research, the 
technology of monoclonal antibodies [131]. Recently they are being used with 
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enormous success in therapies for cancer and autoimmune diseases [132-134].  
Antibody-secreting cells (ASC), plasmablasts and plasma cells produce antibodies in 
secondary lymphoid organs, from where they are distributed via circulatory and 
lymphatic systems throughout the body [135, 136]. Moreover, B cells are key elements 
in developing vaccines because of their remarkable high-specificity and -affinity 
antibody production against a particular antigen, and the capacity to confer 
immunological memory  and mount a greater immune response after re-encountering 
with the same antigen [137, 138]. 
The development of B cells takes place in the bone marrow (BM) from the common 
lymphoid progenitor (CLP) (Figure 2). In contrast to T cells,  they leave the BM fully 
developed but in immature state, expressing IgM as B-cell receptor (BCR) [139]. T 
cells on the other hand, are originated in the BM, but the final stage of development 
takes place in the thymus [140].  Immature B cells drive through the peripheral blood 
[141] and other tissues towards the secondary lymphoid organs, by means of 
chemokines, for example, CXCL13, CCL12, [142], where they finish their maturation 
process, start co-express IgM and IgD and are ready to encounter their specific antigen 
to become activated [143]. Nevertheless, it is fundamental that before leaving the BM 
they undergo the central tolerance test (self-antigen autoreactivity test), and in the 
process of maturation in the peripheral lymphoid organs, pass through the peripheral 
tolerance and are checked a second time. B cells which fail autoreactivity tests are 
deleted by the programmed cell death, apoptosis or become anergic [144-146]. 
1.3.2 Human B-cell phenotyping 
 
After leaving the BM B cells can assume several phenotypes, which characterize 
specific cell stages and fate. For instance, a mature-naïve B cell express CD19+ (pan 
B-cell marker) IgM+IgG+CD24low as surface markers and it is ready to recognize its 
cognate antigen via the BCR (Figure 4 A and B). The encounter of a mature B cell with 
an antigen pre-activates it, leading to the upregulation of co-stimulatory molecules, 
such as CD80, CD86, CD40, CD69 and MHC II as well as the common B-cell markers 
CD19, IgM, IgD, CD24, and others. Following the activation path, B cell may present 
the antigen it captured via MHC II to its cognate follicular T helper cell (Tfh), and thus 
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becoming fully activated [147, 148]. The full activation confers to B cells the ability to 
form germinal centers (GCs) and become antibody secreting cells (ASC) by 
undergoing substantial changes on the cell surface, genetically (class switching, 
somatic hypermutation), morphologically and functionally (antibody secretion)  [136], 
turning them into plasmablasts, with phenotype CD19+CD27high CD38high and CD138- 
and finally into long-lived plasma cells which are CD19low-medIgD-
CD27highCD38highCD138high [149]. Alternatively, they can differentiate into memory B 
cells, CD19+IgD-CD27+. Memory B-cell markers vary according to their different stage 
of differentiation and way of activation, for instance, there are switched, non-switched 
and others stages of memory B cells. [149-151].   
Table 2: Therapeutic approaches and pharmacological regulation of myeloid cells in cancer 
(MDSCs).    
 
Therapeutic treatment 
 
 
Molecular events 
 
 
Effect on myeloid cells 
 
 
Nitrosapin, Triterpenoids 
 
 
Downregulation of ARG1, iNOS, 
and ONOO- 
 
Inhibition of MDSCs suppressive 
effects 
 
Sunitinib, Gemcitabine 
 
STAT3 inhibition and decreasing 
effects of GM-CSF 
 
Inhibition of MDSCs expansion 
 
 
Celecoxib 
 
 
Downregulation of PGE2, CCL2 
and increase expression of 
CXCL10 
 
Inhibition of MDSCs suppressive 
effects 
 
CCL2-specific monoclonal 
antibody 
 
Act on CCL2 binding to CCR2 and 
with VEGFA upregulation 
 
Inhibition of metastatic spread 
 
 
5-fluorouracil, docetaxel, 
vitamin D3 
 
MDSCs apoptosis 
 
Inhibition of MDSCs expansion 
 
 
All-trans retinoic acid 
 
 
Differentiation of immature myeloid 
cells to mature leukocytes 
 
Inhibition of MDSCs accumulation 
 
ARG1: arginase-1; iNOS: Inducible nitric oxide synthase; ONOO-: peroxynitrite; MDSCs: Myeloid-derived 
suppressor cells; STAT3: Signal transducer and activator of transcription 3; GM-CSF: Granulocyte-macrophage 
colony-stimulating factor; CCL, CC-chemokine ligand 2; CCR2, CC-chemokine receptor 2; PGE2: prostaglandin 
E2; VEGFA: Vascular endothelial growth factor A. Adapted from Gabrilovich, Ostrand-Rosenberg [98] 
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Many other combinations of markers are also used to phenotype human B cells and 
they are also used as biomarkers for various diseases involving B cells, such as 
systemic erythematous lupus [152], Sjögrens syndrome [153], and rheumatoid arthritis 
[133, 149]. In addition, B10 or Bregs cells exhibit the intrinsic B-cell activation markers 
plus the capacity to produce and release high amounts of IL-10 cytokine and thereby 
induce Th2 immune responses [48, 154] (Figure 4 A). 
 
Figure 4: Characteristics and interactions of B cells (A) B-cell phenotypic profiles for immature, 
memory B cell and plasma cell. (B) B-cell receptor (BCR) and the linkage of an antigen and co-receptors 
are also represented, for example, CD19 (pan marker for B cells). (C) A B-cell up-taking, processing 
and present an antigen to a cognate Tfh cell, forming a linked recognition followed of the formation of 
germinal centers (GCs). Adapted from Kaminski et al. (2012) [149], Shlomchik and Weisel (2012) [122] 
and Yuseff et al. (2013) [120]. 
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1.2.3 B-cell activation 
 
A naïve mature B cell in a secondary lymphoid organ is subject to encounter its cognate 
antigen and begin its activation process [151, 155, 156]. The first step is the recognition 
of a particular epitope of the antigen via BCR [157]  It may happen via cross-link of the 
receptor by multivalent antigens (Figure 4B), such as lipopolysaccharide (LPS) [158] 
or by mitogens, for instance, poke-weed [159, 160]. The outcome of this type of 
activation, called thymus-independent (TI), is proliferation and differentiation of the TI 
activated B cells into short-lived plasma cells, which can mainly produce IgM as 
antibody, with this type of activation B cells do not develop the ability of somatic 
hypermutation or antibody class-switching. What’s more, the antibodies produced have 
low affinity for the antigen and no immunological memory is developed, however, it is 
controversial [161, 162]. It may be better understood as an B-cell innate response to a 
microbe, because it is fast and intense, delaying then the establishment of an infection 
[163].  
Another way to induce TI B-cell activation is via toll-like receptors (TLRs) agonists, for 
instance, human B cells express in a great deal intracytoplasmic TLR-9 so that CpG 
ODN DNAs can induce B-cell activation. It has been used for the in vitro activation of 
B cells, a combination of CpG ODN and BCRs agonists such as IgM (Fab`)2 portion 
with pronounced success in research [128]. 
The thymus-dependent (TD) activation of B cells is a more complex process, and is 
described as the process after a B cell meeting a microbial antigen, via BCR. It then 
internalizes, processes and presents the antigen via MHC II to a cognate follicular T 
helper cells (Tfh). This process happens in a secondary lymphoid organ, for instance, 
spleen and is a reciprocal communicative interaction between B and T cells [135, 164].   
By presenting antigen to a T cell (the B-cell APC function), the T cell also becomes 
activated and upregulates molecules such as CD40L (CD154), CD28 which link to their 
respective receptors on the B-cell surface, CD40 and CD80 (B7-1) or CD86 (B7-2) 
respectively [151, 165]. In addition, the Tfh also produce cytokines, such as IL-4, IL-
21, IL-2, IL-6, IL-5 and others, which function as growth factor and induce 
differentiation, antibody class-switching and secretion and activation of genes involved 
  
28 
 
in B-cell survival (anti-apoptotic genes), up-regulation of MHC II, and costimulatory 
molecules (B7-1 and B7-2) and formation of germinal centers (GC) [151, 163, 166-
169]. Other proteins involved in the B-cell activation or fate are the cytokines A 
proliferation-inducing ligand (APRIL) and B-cell activating factor (BAFF), they are both 
tumor necrosis factor superfamily ligands (TNFSF ligand) and are remarkably 
important for B-cell activation and fate in homeostasis and diseases such as 
autoimmune diseases and cancer [170, 171].  The former is linked to development and 
survival, and the latter is involved in activation, proliferation, and differentiation [172, 
173] 
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2. Aim of study 
 
MDSCs are key components of the immunosuppressive tumor microenvironment, and 
they have been described as unpleasant components due to their contribution to tumor 
progress, positively correlation with patient tumor burden, and development of 
metastasis. They play also a role in inflammatory, infective diseases and trauma. 
MDSCs are known to suppress the immune function of T cells in several pathological 
conditions and homeostasis. The effects of MDSCs on B cells remain elusive, and the 
pieces of information provided so far, is mainly obtained from studies using murine 
systems, which are sub-optimal of normal human B-cell function or genuine diseases. 
B cells play important roles in several diseases, such as lymphomas, autoimmune 
diseases and infections, they play also a pivotal role in the maintenance of 
homeostasis.  Due to that, it is important to reveal the possible interactions between 
MDSCs-B cells and then make more robust assumptions towards therapeutically 
performances and treatment of pathologies involving these both cells types. 
In light of the foregoing, the aim of this project was to depict the interactions between 
polymorphonuclear-MDSCs and B cells. Using in vitro assays, we performed cell co-
cultures using isolated MDSCs and B cells in different ratios. We applied different ways 
of B-cell activation, one is an unspecific way by using phorbol 12-myristate 13-acetate 
(PMA) plus ionomycin (ION) and the other using specific stimulus, CpG 
oligodeoxynucleotides (ODN CpG) plus IgM (Fab`)2. From the co-cultures, we 
performed B-cell proliferation tests, by following carboxyfluorescein succinimidyl ester 
(CFSE) dilution of the CD19 positive cells by flow cytometry, and collection of 
supernatant to observe the titer of immunoglobulin M (IgM) by ELISA. In addition, we 
applied live-dead tests by using annexin V and propidium iodide (PI). In order to depict 
the mechanism involved in the interactions between PMN-MDSCs and B cells, we 
applied transwell systems to check on cell-contact dependence and tests of inhibitors 
for arginase-1 (Nor-NOHA), iNOs (L-NMMA), ROS (DPI) and IDO (1-MT). To confirm 
physical contact between PMN-MDSC: B cell we used microscopy flow cytometry 
technology (image stream).  
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3. Discussion 
 
The aim and focus here is the investigation of the interactions between human MDSCs 
and B cells in homeostasis. MDSCs exert their suppressive mechanisms in 
pathological conditions, such as chronic inflammation, autoimmune diseases, 
infections and various types of cancers as well as in homeostasis. The tumor 
microenvironment milieu is highly immunosuppressive and a great deal of this 
phenomenon is due to the accumulation and expansion of suppressive myeloid cells, 
mainly MDSCs. These cells are closely related to the patient poor prognosis as well as 
the development of metastasis. They are involved in a complex cell web cross-talk and 
they have been described to regulate T-, DCs, NK-, NKT-cells and neutrophils 
responses [59, 69, 174]. A few studies have been carried out regarding the effects of 
MDSCs on B cells, most of them were conducted using mouse models, which are only 
sub-optimal systems to reflect human B-cell function or genuine diseases [149]. Our 
experimental results in this study reveal that human PMN-MDSCs in a dose-dependent 
fashion and by means of different suppressive mechanisms dampen B-cell function at 
several levels, by suppressing B-cell proliferation and antibody production, depending 
on the B-cell stimulation type. In order to depict the mechanisms involved in these 
interactions we demonstrate that the MDSC-mediated effects are cell contact-
dependent, involve arginase-1, NO, ROS and cell death. All in all, our studies 
established a novel function of PMN-MDSCs by regulating B-cell homeostasis, which 
could have future implications for the immunotherapy approaches. 
3.1 PMN-MDSCs suppress B-cell proliferation and antibody production in a 
dose- and stimulus-dependent manner  
 
To investigate the effects of human MDSCs on B-cell proliferation and antibody 
production we isolated PMN-MDSCs, PMNs (used as control) and B cells and co-
cultured them upon non-specific and specific B-cell stimulation. Our data demonstrate 
that PMN-MDSCs but not PMNs strongly inhibited specific activated (with CpG plus 
IgM) B-cell proliferation, in a dose-dependent fashion. Next, we evaluated the IgM titer, 
and found that MDSCs also significantly decreased IgM secretion also in a dose-
depended manner. Control using conventional human neutrophils had no significant 
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effect on proliferation or IgM secretion. As PMN-MDSCs share common phenotypic 
characteristics with conventional neutrophils, it is important to notice that in a study 
using mice systems it was found that neutrophils interacted and stimulate B cells in the 
marginal zone (MZ B cells) of the spleen (“B cell-helper neutrophils”). MZ B cells 
recognize PAMPs due to poor diversification of BCR and they are considered innate 
ASCs, which produce IgM mainly. Particularly, splenic neutrophils triggered antibody 
production by MZ B cells (IgM) and immunoglobulin class switching to IgG and IgA 
isotypes [175]. This B-cell thymus dependent activation side of the neutrophils, is 
probably due to their capacity to produce BAFF and APRIL cytokines, which are 
CD40L-ralated molecules. Interestingly, neutropenic patients exhibited lower MZ B 
cells, but it is controversially discussed [176, 177].  In respect to MDSCs, recent finds 
based on murine studies point towards an immunosuppression of MDSCs on B-cell 
immune functions in infective diseases, such as acquired immune deficiency syndrome 
(AIDS) and BM5 retrovirus infection [114, 178]. Moreover, autoimmune 
disease/autoimmune arthritis was also target of instigation for MDSC-B-cell 
interactions. The study showed in a mouse model hat MDSCs suppressed autologous 
B-cell proliferation and antibody production [116].  Unspecific stimulated B-cells with 
PMA and ionomycin was not affected by PMN-MDSCs suppressive mechanisms, as 
the direct and simultaneous stimulation of protein kinase C (PKC) and Ca2+ opening 
channels is probably too strong to be affected.  
3.2 PMN-MDSC-mediated B-cell suppression is cell-contact dependent and 
involves arginase-1, nitric oxide, reactive oxygen species, cell death. 
MDSCs use a variety of molecular mechanisms to suppress T cells, some of the 
mechanisms are cell-contact dependent and involve ROS, iNOS, arginase-1, cytokines 
and other factors. [51, 98, 179]. An interesting and novel aspect is that MDSCs are 
also involved in the induction of Bregs (IL-10 producing B cells) by means of arginase-
1 and iNOS production [117]. Here we also demonstrate that PMN-MDSCs require 
cell-to-cell contact to suppress B-cell proliferation by using transwell inserts systems. 
Transwell separation of PMN-MDSCs from CpG/IgM stimulated B cells, restored B-cell 
proliferation compared to the cell-to-cell contact cultures. This phenomenon indicates 
contact dependence, and was confirmed by proliferation assays (CFSE and flow 
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cytometry). Microscopic flow cytometry (Image Stream) confirmed the cell contact 
between B cells and PMN-MDSCs. Investigations using mouse systems further 
support to our findings. To give illustration of that, in the rheumatoid arthritis studies 
performed by Crook et al. (2015) [116], MDSCs required cell contact in order to inhibit 
B-cell proliferation. In contrast, it has been published that B-cell lymphopoiesis can be 
inhibited by MDSCs contact independently by  the MDSCs production of IL-1 [180].  
A key approach to depict MDSCs suppressive functions, is by inhibiting their 
mechanisms of suppression [92, 102, 181, 182]. In this regard, we applied inhibitors 
for arginase-1 (Nor-NOHA), iNOS (L-NMMA), NADPH/ROS (DPI) and IDO (1-methyl-
D-tryptophan (1-MT)) in the cell culture with B cells and PMN-MDSCs in different ratios. 
Inhibition of arginase-1 and iNOS restored B-cell proliferation to almost 100% of the 
baseline B-cell proliferation. DPI effects were less pronounced; however, we could still 
observe a significant recovery in B-cell proliferation. Inhibition of IDO with 1-MT did not 
result in recovery of B-cell proliferation, as it seems to be toxic to B cells, as it is 
supported by Pigott and Mandik-Nayak (2012) [183]. Studies using murine models 
support the involvement of MDSCs` arginase-1, NO and ROS in B-cell suppressive 
functions by means of inhibitors usage as well as the involvement of the negative-
checkpoint regulator V-domain Ig suppressor of T-cell activation (VISTA). In addition, 
by using L-NMMA, it was also described the contribution of iNOS/NO, arginase-1 (Nor-
NOHA) and IL-10 in inhibition of B-cell proliferation and responsiveness [114, 115, 178, 
180]. To our knowledge, there is no indication that ROS inhibition has been directly 
tested on MDSCs-B cells analysis, but in previous studies of our lab involving MDSCs-
T cells, DPI has successfully been applied to inhibit ROS production of MDSCs [102, 
184]. 
Besides the proliferative and IgM evaluations, we also demonstrate here that human 
PMN-MDSCs regulate B-cell death of CpG/IgM activated. We observed a decrease in 
B-cell apoptosis in presence of MDSCs. Moreover, we also show a significant increase 
on B-cell necrosis. No differences were found in co-culture with conventional PMNs. 
Information that MDSCs induce B-cell death is scarce. It is described that MDSCs 
promote T-cell apoptosis, nonetheless. It is also proclaimed that MDSCs promote T-
cell death via a mechanism involving IDO in a breast cancer study [93]. In a review 
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article, Rodriguez and Ochoa (2008) [66] suggested that the peroxynitrites originated 
from MDSCs as product of ROS and NO reactions due to the deprivation of L-arginine, 
lead to T-cell death. Our finds showed that the B-cell death profile is skewed to necrosis 
rather than apoptosis. It may be explained due to the fact that MDSCs` oxygen and 
nitrogen species additionally to low levels of L-arginine, accelerate the physiological 
cell-death fate or directly induce necrosis. The B-cell death was decreased by using 
transwell inserts as well as in the presence of the inhibitors such as L-NMMA, Nor-
NOHA and DPI. 
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4. Conclusion  
In conclusion, our study demonstrates that the suppressive potential of human MDSCs 
is not restricted to T-, DC, NK-, or NKT-cell responses, but also regulates B cells. PMN-
MDSCs were found to regulate B-cell proliferation and antibody production, depending 
on the B-cell stimulus. Mechanistically, these effects involved cell-to-cell contact, cell 
death, arginase-1, NO and ROS indicating that the interactions between PMN-MDSCs 
and B cells involve multiple mechanisms. Taken together, our finds help to shed light 
on future investigations to reveal in deep the MDSCs-B-cell interactions, and in this 
way to bring novel and significant immunotherapeutic insights, for instance, in 
autoimmune diseases to dampen exacerbate B-cell responses and autoantibody 
production. Future studies in preclinical disease models and patients are warranted to 
address this potential role of MDSCs as regulators of B-cell activities. 
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Abstract 20 
Myeloid-derived suppressor cells (MDSCs) are key regulators of adaptive immunity by 21 
suppressing T-cell functions. However, their potential action on or interaction with B cells 22 
remained poorly understood. Here we demonstrate that human polymorphonuclear MDSCs 23 
differentially modulate B-cell function by suppressing B-cell proliferation and antibody 24 
production. We further demonstrate that this MDSC-mediated effect is cell contact dependent and 25 
involves established mediators such as arginase-1, nitric oxide (NO), reactive oxygen species 26 
(ROS) as well as B-cell death. Collectively, our studies provide novel evidence that human 27 
MDSCs modulate B cells, which could have future implications for immunotherapy approaches. 28 
 29 
Key words:  myeloid-derived suppressor cells, MDSCs, B cells 30 
 31 
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1. Introduction 56 
Myeloid-derived suppressor cells (MDSCs) are innate immune cells that are functionally 57 
characterized by their capacity to dampen T-cell responses [1,2]. Phenotypically, MDSCs are a 58 
heterogeneous population and comprise a neutrophilic/polymorphonuclear (PMN-MDSC) and a 59 
monocytic (M-MDSC) subset as defined by their respective surface marker profiles [3]. In humans, 60 
polymorphonuclear MDSCs represent the predominant subtype [4,5] and have been studied in 61 
several forms of cancer as well as in infections, auto-immune and auto-inflammatory disease 62 
conditions [1,6].  63 
While initially MDSCs were found to suppress CD4+ and CD8+ T-cell responses, 64 
subsequent investigations expanded their role by demonstrating that MDSCs were also involved 65 
in the regulation of and interaction with natural killer (NK) cells, dendritic cells (DC), neutrophils, 66 
macrophages and natural killer T (NKT) cells [7-9]. The molecular and cellular mechanisms 67 
involved in MDSC generation and function seem to be diverse and complex, but major mediators 68 
described to be involved so far include arginase 1 activity (arginine deprivation), reactive oxygen 69 
species (ROS), nitric oxide synthase (NO), indoleamine 2,3-dioxygenase (IDO) and tumor 70 
necrosis factor alpha (TNF-α) [1,6,8,9]. Recently, the transcriptional regulation and the proteome 71 
landscape of MDSCs have further deepened our insights into their generation, homeostasis and 72 
regulation [10,11]. 73 
In spite of multiple MDSCs-immune cell interactions described [7-9], the potential role of 74 
MDSCs in regulating B cells, as key adaptive immune cell population, remained poorly 75 
understood. Several recent observations already suggested that MDSCs and B cells functionally 76 
interact in mice [12-16], but the characteristics of human MDSCs-B-cell interactions and the 77 
underlying mechanisms have not been defined yet. 78 
Lelis et al. 
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Here we demonstrate that human PMN-MDSCs differentially regulate key B-cell 79 
functions, particularly B-cell proliferation and antibody production, depending on the B-cell 80 
stimulus. We further demonstrate that this MDSC-mediated effect is cell contact dependent and 81 
involves arginase-1, NO, ROS and cell death.  82 
  83 
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2. Material and Methods 84 
2.1. Cell isolation 85 
The study was conducted at the University Children’s Hospital Tuebingen (Germany). All study 86 
methods were approved by the local ethics committee. Buffy coats were provided by DRK-87 
Blutspendedienst Baden-Württemberg-Hessen Institute, Ulm, Germany. Peripheral blood 88 
mononuclear cells (PBMCs) and (high-density) polymorphonuclear leukocytes (PMNs) were 89 
prepared from blood samples by Ficoll density gradient sedimentation (Biochrome). After one 90 
washing step in RPMI 1640 medium (Biochrome), erythrocytes were lysed in Lysis buffer 91 
(0.829% ammonium chloride, 0.1% potassium hydrogen carbonate, 0.00372% 92 
Ethylenediaminetetraacetic acid disodium salt dihydrate in water). PMN-MDSCs were isolated 93 
and characterized as described in our previous studies [17-19]. In brief, PMN-MDSCs in the Ficoll 94 
PBMC interphase fraction were labelled with anti-CD66b-fluorescein isothiocyanate (FITC) and 95 
isolated by an anti-FITC sequential magnetic bead separation step using the autoMACS®Pro 96 
Separator (Miltenyi Biotec), according to the manufacturer’s protocol. The B-cell isolation 97 
strategy was based on previous protocols [20] using negative selection from the PBMCs fraction. 98 
Therefore, cells were labelled with anti-CD43-FITC followed by anti-FITC sequential magnetic 99 
bead separation using autoMACS®Pro Separator. One further labelling step with a combination 100 
of anti-CD3 magnetic beads and anti-CD14 magnetic beads was performed, followed by a second 101 
magnetic bead separation step using autoMACS®Pro Separator. Microbeads against CD3, CD14 102 
or FITC were purchased from Miltenyi Biotec.  103 
 104 
 105 
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2.2. Cell culture, CFSE labeling and B-cell activation 106 
Isolated B cells were stained with carboxyfluorescein-succinimidyl ester (CFSE, Life 107 
Technologies) at day 0, according to the manufacturer’s protocol. For the CD86 and HLA-108 
DR/MHC-II receptor analysis, no CFSE-staining was performed. For activation, isolated B cells 109 
were stimulated with PMA (1 µM, Sigma) plus ionomycin (0.5 µg/mL, Sigma) or 5 µg/mL IgM 110 
(Jackson ImmunoResearch) plus 2.5 µg/mL CpG ODN (InvivoGen). 5 x 105  B cells per well were 111 
seeded in RPMI-1640, in a 48-well microtitre plate (Life Sciences) and PMN-MDSCs or PMNs 112 
as a control in RPMI-1640 were co-cultured at the ratios 1:5, 1:2 or 1:1 (MDSC:B cell). The 113 
transwell assay was performed using a transwell insert system (6.5 mm diameter inserts with 0.4 114 
μm pores, Greiner BIO-ONE). Where indicated, inhibitors of Arginase-1, iNOS, ROS and IDO 115 
production, namely Nω-hydroxy-nor-Arginine 300 µM (Nor-NOHA/Enzo Life Sciences), L-NG-116 
monomethyl arginine citrate 300µM (L-NMMA/Calbiochem) or Methyl-Tryptophan 500 µM (1-117 
MT/Sigma Aldrich) were added to the cell culture (for details see Table 1 and [21]). Where 118 
indicated, diphenyleneiodonium chloride 1 µM (DPI/Sigma Aldrich) was incubated for 1 h at 37°C 119 
with PMN-MDSCs before these cells were washed once to get rid of excessive DPI as described 120 
in Table 1 and previously [22,23]. The cell culture was supplemented with 10 % human serum, 2 121 
mM L-glutamine (Millipore) and 100 U/mL penicillin/streptomycin (Millipore). After 120 h of 122 
incubation at 37°C and 5 % CO2, cells were harvested and supernatants were frozen at -20°C. 123 
 124 
2.3. Immunoglobulin M analysis 125 
Immunoglobulin M (IgM) analysis in collected supernatants from the CFSE-culture was 126 
performed using human IgM Ready-SET-GO from eBioscience, according to the manufacturer’s 127 
protocol with the exception that supernatants were used in a 1:100 dilution.  128 
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2.4. Flow cytometry 129 
For B-cell stainings, harvested cells were stained with a PE-conjugated (Biolegend) or FITC-130 
conjugated (BD Biosciences) anti-CD19-antibody for 10 min. To assess B-cell proliferation, the 131 
CFSE fluorescence intensity was analyzed. For necrosis and apoptosis studies, propidium iodide 132 
(PI, BD Bioscience) and Annexin V (BD Bioscience) stainings were performed as to the protocols 133 
of the manufacturer, respectively. For the analysis of cell surface receptors, CD86-receptor was 134 
stained using anti-CD86-APC antibody (Biolegend) and MHCII-receptors were stained with anti-135 
HLA-DR-PerCP (Biolegend). Flow cytometry was performed on a FACS Calibur (BD). Results 136 
were expressed as percent of positive cells and mean fluorescence intensity (MFI). Calculations 137 
were performed with BD CellQuestPro analysis software. Supplementary Figure 1 shows the flow 138 
cytometric gating strategy. 139 
 140 
2.5. ImageStream 141 
The Image Streamx mk II (Merck Millipore) system with the INSPIRE instrument software was 142 
used for acquisition and the IDEAS® data analysis software for image analysis. In brief, human B 143 
cells and PMN-MDSCs were isolated from human peripheral blood. Following incubation, cells 144 
were stained for CD66b-PE (Biolegend) for PMN-MDSCs, CD19-FITC (BD) for B cells and 145 
DAPI for nuclear stain (ThermoFisher). Cell doublets were identified, a valley mask on the DAPI 146 
image was created in order to define the contact region between conjugates and an “interface” 147 
mask was applied in order to define the overlap area between MDSCs and B cells. MDSC-B-cell 148 
interactions were visualized.  149 
 150 
 151 
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2.6. Statistical analysis 152 
Statistical analysis was performed using GraphPad Prism version 6.0. Differences between the 153 
groups were determined by ANOVA when comparing 5 groups and un-paired, two-tailed 154 
Student’s t-test for comparing 2 groups. All results are presented as mean + SEM. A P value < 155 
0.05 was considered significant. 156 
 157 
 158 
 159 
 160 
 161 
  162 
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3. Results  163 
 164 
3.1. PMN-MDSCs suppress B-cell proliferation and antibody production in a dose- and 165 
stimulus-dependent manner 166 
We systematically assessed the potential of isolated human PMN-MDSCs to suppress B-cell 167 
responses. PMN-MDSCs were defined by their low-density, respective surface markers and by 168 
their characteristic to suppress T-cell responses as published previously by our group [17-19]. 169 
Conventional (high-density) non-MDSC human PMNs cells were used as control cell population. 170 
Initially, we tested the effect of MDSCs on non-specific B-cell activation, using PMA and 171 
ionomycin. These results demonstrated that neither PMN-MDSCs nor control neutrophils/PMNs 172 
had an effect on PMA/ionomycin-induced B-cell proliferation (Figure 1A). Next, we analyzed the 173 
effect of MDSCs on specific B-cell activation, elicited by IgM F(ab`)2 plus ODN CpG, as 174 
described previously [24,25]. These studies, in contrast to our findings on PMA/ionomycin-175 
activated B-cell proliferation, demonstrated that PMN-MDSCs dose-dependently suppressed B-176 
cell proliferation, with the most potent suppression observed at 1:1 ratio, whereas control PMNs 177 
did not (Figure 1B). Furthermore, we investigated whether MDSCs modulate the expression of co-178 
stimulatory molecules and activation markers on the surface of B cells. These studies demonstrated 179 
that PMN-MDSCs decreased the surface expression of IgM F(ab`)2/CpG-induced CD86 180 
expression on human B cells in a dose dependent fashion, but had no significant effect on HLA-181 
DR/MHC-II expression (Figure 2A). Finally, we assessed whether MDSCs affect antibody 182 
production by B cells. These data demonstrated that PMN-MDSCs significantly suppressed IgM 183 
F(ab`)2/CpG-induced-IgM production. Conventional PMNs did not show any significant effect on 184 
IgM suppression (Figure 2B). Taken together, these data demonstrated that human PMN-MDSCs 185 
modulate B-cell responses in a dose- and B-cell stimulus-dependent manner. 186 
Lelis et al. 
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3.2. PMN-MDSC-mediated B-cell suppression is cell contact dependent and involves arginase-1, 187 
nitric oxide, reactive oxygen species and cell death 188 
Next, we sought to dissect the mechanisms involved in MDSC-mediated B-cell suppression. Since 189 
MDSCs have been described to mediate target cell suppression through cell contact as well as 190 
paracrine soluble mediator mechanisms, we analyzed whether MDSC-mediated B-cell suppression 191 
required cell-to-cell contact by using a Transwell co-culture system as applied previously by our 192 
group [17]. These investigations demonstrated that MDSC-mediated suppression of B-cell 193 
proliferation required cell-to-cell contact, since Transwell-separated B cells were not affected by 194 
increasing numbers of PMN-MDSCs (Figure 3A). Imagestream analysis confirmed the physical 195 
interaction of PMN-MDSCs and B cells in our assays (Supplementary Figure 2). In a subsequent 196 
step, we reasoned which MDSC-related factors are involved in MDSC-mediated cell contact 197 
dependent B-cell proliferation. Based on previous studies [21,23] we focused on arginase-1, NO, 198 
ROS and IDO as factors potentially involved in T-cell suppression. For this purpose, we pretreated 199 
PMN-MDSCs by using specific inhibitors for these mediators such as Nor-NOHA, L-NMMA, 200 
DPI and 1-MT, respectively, in MDSC-B-cell co-culture assays as indicated in Table 1. These 201 
investigations demonstrated that these inhibitors, with exception of 1-MT, dampened the effect of 202 
MDSCs on B-cell proliferation (Figure 3B). In addition, we investigated whether the effects of 203 
MDSCs are related to induction of B-cell apoptosis and/or necrosis by flow cytometry using 204 
Annexin V and propidium iodide (PI) staining (Figure 4). These analyses demonstrated that human 205 
PMN-MDSCs, in high concentrations, prevented B-cell apoptosis (Figure 4A), but instead B-cell 206 
necrosis was induced when co-cultured at 1:2 and 1:1 ratios (Figure 4B). No pronounced effect 207 
was observed in late apoptosis when assessed by the double positive B cells for Annexin V and PI 208 
(Figure 4C). Again, conventional PMNs had no significant effect on B-cell apoptosis or necrosis 209 
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(see right panels of Figure 4A-C). In line with the effect on proliferation and antibody production 210 
the PMN-MDSC-induced cell death of the B cells was also cell contact dependent (Figure 5A). 211 
Consistently, inhibitors of the MDSC effector pathways also interfered with the MDSC-mediated 212 
effect on B-cell death (Figure 5B). Collectively, these studies demonstrate that human PMN-213 
MDSCs dampen B-cell proliferation through a mechanism involving cell-to-cell contact, B cell 214 
death, arginase-1, NO and ROS. 215 
216 
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4. Discussion  217 
MDSCs have been described to regulate T-, DC, NK-, NKT-cell and neutrophil responses [7-9]. 218 
However, their potential effect on human B-cell homeostasis and function remained largely 219 
elusive. Here we demonstrate that human PMN-MDSCs dose-dependently and differentially 220 
regulate B-cell function at several levels, by suppressing B-cell proliferation and antibody 221 
production, depending on the B-cell stimulus. Mechanistically, we also demonstrate that the 222 
MDSC-mediated effects are cell contact-dependent and involve arginase-1, NO, ROS and cell 223 
death. Collectively, our studies established a novel function of PMN-MDSCs by regulating B-cell 224 
homeostasis, which could have future implications for immunotherapy approaches. 225 
Evidence on MDSC-B-cell interactions is scarce. Polymorphonuclear MDSCs share 226 
common phenotypic characteristics with conventional neutrophils. In mice, neutrophils were 227 
found to interact and stimulate B cells in the marginal zone of the spleen („B cell-helper 228 
neutrophils“) [26]. Particularly, splenic neutrophils triggered immunoglobulin class switching and 229 
antibody production by activating B cells. Interestingly, neutropenic patients exhibited lower 230 
marginal zone B cells. While these intriguing findings were challenged by another study which 231 
failed to detect functional “B cell-helper neutrophils” in the human spleen, the potential interaction 232 
between neutrophils and B cells remains an active and controversial field [27]. 233 
Regarding MDSCs, recent murine studies point towards an interaction of MDSCs and B 234 
cells in the contexts of murine acquired immune deficiency syndrome (AIDS) and BM5 retrovirus 235 
infection [13,14,28] and autoimmune disease / autoimmune arthritis [12]. In the latter study, 236 
MDSCs in a mouse model of autoimmune arthritis suppressed autologous B-cell proliferation and 237 
antibody production via NO and prostaglandin E2 (PGE2) and in a cell contact dependent manner. 238 
Moreover, IL-1-producing murine MDSCs were found to inhibit B-cell lymphopoiesis [15]. In 239 
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addition, tumor-evoked B regulatory cells (tBregs) were found to activate the function of MDSCs 240 
through a TGF-beta receptor type-1/2 -mediated mechanism [29]. In murine models, MDSCs co-241 
cultured with splenocytes triggered the expansion of IL-10-producing B cells, which was blocked 242 
upon inhibition [30]. In patients with non-small cell lung carcinoma, interleukin-10 (IL-10) 243 
producing Breg cells correlated positively with MDSCs [31].  244 
Despite these intriguing insights into MDSC-B-cell interactions, these concepts were 245 
mainly based on findings in the murine system, while human data on the reciprocal MDSC-B- cell 246 
relationship remained elusive. Here we comprehensively dissected the effect of human PMN-247 
MDSCs on B-cell homeostasis and function. Our studies demonstrate that human MDSCs supress 248 
B-cell proliferation and antibody production in a dose- and B cell stimulus-dependent manner. 249 
Furthermore, our investigations showed that, in line with studies on MDSC-T-cell interactions, 250 
MDSC-mediated B-cell suppression was cell-cell contact dependent and involved soluble 251 
mediators such as arginase-1, NO and ROS as well as cell death. Control conventional human 252 
neutrophils had no significant effect on proliferation, B-cell death or effect on IgM production. 253 
The cellular mechanism(s) underlying this functional difference between human PMN-MDSCs 254 
and conventional human neutrophils in regulating B-cell functions remain to be dissected in future 255 
investigations. However, based on previous studies demonstrating that both cell-to-cell contact / 256 
cellular proximity and the soluble mediators above mentioned were involved in T-cell suppressive 257 
activities of a distinct PMN-MDSC-like neutrophil subset induced during acute systemic 258 
inflammation in humans [32], we tempt to speculate that arginase-1, iNOS and ROS activities may 259 
represent common key mechanisms involved in PMN-MDSC-mediated suppression of both T- 260 
and B-cell responses.  261 
 262 
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5. Conclusion 263 
In summary, our studies demonstrate that the suppressive potential of human MDSCs is not 264 
restricted to T-, DC, NK-, or NKT-cell responses, but also regulates B cells at several levels. PMN-265 
MDSCs were found to regulate B-cell proliferation and antibody production, depending on the B-266 
cell stimulus. Mechanistically, these effects involved cell-to-cell contact, cell death, arginase-1, 267 
NO and ROS. Based on these findings, the in vivo induction / expansion or the adoptive transfer 268 
of sorted MDSCs may represent a novel immunotherapeutic tool in autoimmune diseases to 269 
dampen B-cell responses and autoantibody production. Future studies in preclinical disease models 270 
and patients are warranted to address this potential role of MDSCs as regulators of B-cell activities. 271 
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Figure legends 416 
Fig. 1. MDSCs suppress B-cell proliferation in a dose- and stimulus-dependent manner 417 
Human polymorphonuclear MDSCs (PMN-MDSCs), conventional neutrophils (PMNs) and B 418 
cells were isolated from buffy coats and co-cultured at 1:5, 1:2 and 1:1 ratios (MDSCs:B cells).  419 
Isolated B cells cultured in medium only served as negative controls and when cultured in presence 420 
of PMA (1 µM) plus ionomycin (0.5 µg/mL) or IgM F(ab`)2 (5 µg/mL) plus CpG (2.5 µg/mL) 421 
served as positive controls. (A) Effect of MDSCs/PMNs on non-specific PMA/ionomycin-induced 422 
B-cell proliferation (CFSE assay, n=13). (B) Effect of MDSCs/PMNs on specific IgM 423 
F(ab`)2/CpG-induced B-cell proliferation (CFSE assay, n=9). Bars represent means +SEMs; *P< 424 
0.05. 425 
 426 
Fig. 2. MDSCs supress B-cell antibody production in a dose- and stimulus-dependent 427 
manner 428 
Human polymorphonuclear MDSCs (PMN-MDSCs), conventional neutrophils (PMNs) and B 429 
cells were isolated from buffy coats and co-cultured at 1:5, 1:2 and 1:1 ratios (MDSCs : B cells).  430 
Isolated B cells cultured in medium only served as negative controls and when cultured in presence 431 
of IgM F(ab`)2 (5 µg/mL) plus CpG (2.5 µg/mL) served as positive controls. (A) Effect of MDSCs 432 
on IgM F(ab`)2/CpG-induced surface expression of CD86 and MHC-II (HLA-DR) (FACS, n=6). 433 
(B) Effect of MDSCs/PMNs on IgM F(ab`)2/CpG-induced IgM levels (ELISA, n=8). Bars 434 
represent means +SEMs; *P< 0.05 435 
 436 
 437 
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Fig. 3. MDSC-mediated B-cell suppression is cell contact-dependent and involves soluble 438 
mediators such as arginase-1, nitric oxide (NO) and reactive oxygen species (ROS)  439 
Human polymorphonuclear MDSCs (PMN-MDSCs) and B cells were isolated from buffy coats 440 
and co-cultured at 1:5, 1:2 and 1:1 ratios (MDSCs:B cells). Isolated B cells cultured in medium 441 
only served as negative controls and when cultured in presence of IgM F(ab`)2 (5 µg/mL) plus 442 
CpG (2.5 µg/mL) served as positive controls (white bars). (A) The effect of transwell filters (0.4 443 
μm pore size, n=8, light-gray bars) was compared to the cell to cell contact tests (n=9, dark-gray 444 
bars). In (B) the effect of arginase-1, iNOS, ROS and IDO inhibition (using Nor-NOHA, L-445 
NMMA, DPI and 1-MT, respectively; n=8; dark-gray to light-gray bars gradient) on MDSCs is 446 
depicted. Except for 1-MT, all inhibitors mediated suppression of IgM F(ab`)2/CpG-induced B-447 
cell proliferation (CFSE assay) when compared to the positive control (CFSE assay, n=9,white 448 
bar). Bars represent means +SEMs; *P< 0.05. 449 
 450 
Fig. 4. MDSC-mediated B-cell suppression involves cell death 451 
Human B cells and polymorphonuclear MDSCs (PMN-MDSCs) or conventional neutrophils 452 
(PMNs) were isolated from buffy coats and co-cultured at 1:5, 1:2 and 1:1 ratios (MDSCs:B cells). 453 
Isolated B cells cultured in medium only served as negative controls and when cultured in presence 454 
of IgM F(ab`)2 (5 µg/mL) plus CpG (2.5 µg/mL) served as positive controls. The effect of 455 
MDSCs/PMNs on specific IgM F(ab`)2/CpG-induced B-cell (A) apoptosis (Annexin V staining, 456 
CFSE assays, n=9), (B) necrosis (PI staining, CFSE assays, n=9) and (C) late apoptosis (Annexin 457 
V, PI staining, CFSE assays, n=9). Bars represent means +SEMs; *P< 0.05. 458 
 459 
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Fig. 5. MDSC-mediated induction of B-cell death is cell contact-dependent and involves 460 
arginase-1, nitric oxide (NO) and reactive oxygen species (ROS)  461 
Human polymorphonuclear MDSCs (PMN-MDSCs) and B cells were isolated from buffy coats 462 
and co-cultured at 1:5, 1:2 and 1:1 ratios (MDSC:B cells). Isolated B cells cultured in medium 463 
only served as negative controls and when cultured in presence of IgM F(ab`)2 (5 µg/mL) plus 464 
CpG (2.5 µg/mL) served as positive controls. (A) The effect of transwell filters (0.4 μm pore size, 465 
n=8, light-gray bars) was compared to the cell to cell contact tests (n=9, dark-gray bars). In (B) the 466 
effect of arginase-1, iNOS, ROS and IDO inhibition (using Nor-NOHA, L-NMMA, DPI and 1-467 
MT respectively, n=8 dark gray to light gray bars gradient) on MDSCs is depicted. All inhibitors 468 
mediated suppression of IgM/CpG-induced B-cell death as determined by PI staining compared to 469 
the positive control (CFSE assays, n=9, white bar). Bars represent means +SEMs; *P< 0.05).  470 
 471 
 472 
 473 
 474 
 475 
 476 
 477 
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Table 1: Description of the inhibitors used with respective concentrations, supplying companies, 479 
targets and references  480 
Inhibitor Concentration 
(µM) 
Company Target 
Nor-NOHA* 300 Enzo Life Sciences arginase-1 
L-NMMA* 300 Calbiochem iNOS 
DPI* 1 Sigma Aldrich ROS 
1-MT* 500 Sigma Aldrich IDO 
*Added to the cell culture and incubated at 37°C, 5%CO2 for 120 hours. 481 
** DPI was incubated for 1 h at 37°C with PMN-MDSCs before cells were washed once to get 482 
rid of excessive DPI as reported previously [22]. 483 
 484 
 485 
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Highlights  
● Myeloid-derived suppressor cells (MDSCs) are important mediators of the immune cells. 
● MDSCs impair B-cell proliferation and induce B-cell death  
● MDSCs decrease B-cell IgM responses and down regulate the expression of important 
activation surface markers 
● MDSCs use of reactive oxygen species (ROS), arginase-1, and nitric oxide (NO) to 
modulate B-cell immune responses 
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Supplementary Figure 1
Supplementary Figure 1. Flow cytometry strategy: Human polymorphonuclear MDSCs (PMN-MDSCs) and B
cells were isolated from buffy coats and co-cultured at 1:5, 1:2 and 1:1 ratios (MDSC:B cells). Isolated B cells
cultured in medium only served as negative controls and when cultured in presence of IgM F(ab`)2 (5 µg/mL)
plus CpG (2.5 µg/mL) served as positive controls. The plots on the left side depict the Side scatter (SSC) vs
Forward scatter (FSC), followed by the exclusion of the dead or PI positive cells then the CD19, CFSE positive
cells. On the right side, histograms are depicted showing the inhibition of PMN-MDSC on the B-cell proliferation
in a dose-dependent manner, comparing to the positive control.
Supplementary Figure 2.
A.
B.
C.
Supplementary Figure 2. MDSC – B cell interactions
Physical MDSC-B cell interactions were visualized by using Image Stream
technology. In brief, human B cells and PMN-MDSCs were isolated from human
peripheral blood and stained for CD66b (MDSCs), CD19 (B cells) and DAPI
(nucleus). (A) Doublets were identified by plotting Aspect ratio vs Area of the
Brightfield image. (B) A valley mask on the DAPI image and an interface mask
(shown in purple) on CD66b+ PE cells were created to define contact area
between cell conjugates (C) Upper panel: From all doublets the single CD66b+
cell population was isolated by plotting Area vs Aspect ratio of CD66b signal.
Lower panel: Representative images of MDSC – B cell contacts / immune
synapses are shown.
  
 
 
 
 
 
 
 
 
 
 
Paper 2 
 
 
Singh A, Lelis F, Braig S, Schäfer I, Hartl D, Rieber N. Differential Regulation of 
Myeloid-Derived Suppressor Cells by Candida Species. Frontiers in Microbiology. 
2016;7:1624.  
 
fmicb-07-01624 October 7, 2016 Time: 15:23 # 1
ORIGINAL RESEARCH
published: 13 October 2016
doi: 10.3389/fmicb.2016.01624
Edited by:
Oscar Zaragoza,
Instituto de Salud Carlos III, Spain
Reviewed by:
Attila Gacser,
University of Szeged, Hungary
Jeanette Wagener,
University of Aberdeen, UK
*Correspondence:
Anurag Singh
anurag.singh@med.uni-tuebingen.de
†These authors have contributed
equally to this work.
Specialty section:
This article was submitted to
Fungi and Their Interactions,
a section of the journal
Frontiers in Microbiology
Received: 01 August 2016
Accepted: 29 September 2016
Published: 13 October 2016
Citation:
Singh A, Lelis F, Braig S, Schäfer I,
Hartl D and Rieber N (2016)
Differential Regulation
of Myeloid-Derived Suppressor Cells
by Candida Species.
Front. Microbiol. 7:1624.
doi: 10.3389/fmicb.2016.01624
Differential Regulation of
Myeloid-Derived Suppressor
Cells by Candida Species
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Myeloid-derived suppressor cells (MDSCs) are innate immune cells characterize
their ability to suppress T-cell responses. Recently, we demonstrated that the hu
pathogenic fungi Candida albicans and Aspergillus fumigatus induced a distinct su
of neutrophilic MDSCs. To dissect Candida-mediated MDSC induction in more de
we studied the relative efficacy of different pathogenic non-albicans Candida spe
to induce and functionally modulate neutrophilic MDSCs, including C. glabrata
parapsilosis, C. dubliniensis, and C. krusei. Our data demonstrate that the exte
MDSC generation is largely dependent on the Candida species with MDSCs indu
by C. krusei and C. glabrata showing a higher suppressive activity compared to MD
induced by C. albicans. In summary, these studies show that fungal MDSC induc
is differentially regulated at the species level and differentially affects effector T
responses.
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INTRODUCTION
Candida species cause one of the most prevalent fungal infections worldwide (Pfaller and Diekema,
2007; Brown et al., 2012). Among various Candida species, Candida albicans has been the model
organism for the most research studies focused on immunity against Candida infections (Papon
et al., 2013). However, the genus Candida consists of multiple species that show a considerable
variation in terms of their virulence and phenotype and recent studies showed that particularly
diseases caused by NAC species are on the rise (Merseguel et al., 2015).
While C. albicans is well characterized in terms of recognition through PRRs mainly CLRs
like Dectin-1, Dectin-2, mannose receptor (MR) and Mincle (Brown, 2010; Plato et al., 2015),
recognition of NAC species is less precisely defined. In contrast to C. albicans, phagocytosis
of C. parapsilosis by neutrophils was not impaired following Dectin-1 blockade in vitro
(Linden et al., 2010) and, dectin-1−/− bone marrow macrophages showed no defect in binding
to C. glabrata (Kuhn and Vyas, 2012). Interestingly, studies indicated that Dectin-2 also
played a more important role in C. glabrata infection than Dectin-1 (Ifrim et al., 2014).
Abbreviations: CFSE, Carboxyfluoresceinsuccinimidyl ester; DPI, Diphenyleneiodonium chloride; ELISA, Enzyme-linked
immunosorbent assay; FACS, Fluorescence-activated cell sorting; GM-CSF, Granulocyte-macrophage colony-stimulating
factor; G-MDSCs, Granulocytic myeloid-derived suppressor cells; IL-, Interleukin; MACS, Magnetic-activated cell sorting;
MDSCs, Myeloid-derived suppressor cells; M-MDSCs, Monocytic myeloid-derived suppressor cells; NAC, Non-albicans
Candida; PBMCs, Peripheral blood mononuclear cells; PRR, Pattern recognition receptor; ROS, Reactive oxygen species.
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There is also some evidence that T-cell responses are differentially
involved in immunity to NAC species. For example, C. albicans
and C. parapsilosis were shown to induce different T-cell
responses (Tóth et al., 2013), but underlying mechanisms by
which different Candida species exert a differential immune
response remained elusive.
Myeloid-derived suppressor cells are characterized by their
ability to suppress T-cell responses and have mainly been
studied in cancer (Bronte, 2009; Gabrilovich and Nagaraj, 2009).
However, expansion and involvement of MDSCs has also been
reported during various infectious disease conditions, such as
polymicrobial sepsis, tuberculosis, and Staphylococcus aureus
infections (Delano et al., 2007; Du Plessis et al., 2013; Tebartz
et al., 2014). Recently, we showed that C. albicans induces a
distinct subset of neutrophilic myeloid-derived suppressor cells
(G-MDSCs) which is mediated by a Dectin-1/CARD9 signaling
pathway, leading to dampening of T-cell and NK-cell responses
(Rieber et al., 2015).
To further broaden our understanding of how MDSCs play
a role in modulating the host immune response to Candida
infections, we studied the relative efficacy of different pathogenic
NAC species to induce neutrophilic MDSCs, including
C. glabrata, C. krusei, C. parapsilosis, and C. dubliniensis.
Our data demonstrate that the generation of MDSCs is
largely dependent on the Candida species and morphotype.
Further results also show, that Dectin-1 but not Dectin-2 has an
important role during NAC induced MDSC generation.
MATERIALS AND METHODS
Study Subjects
The study was conducted at the University Children’s Hospital
Tübingen (Germany). MDSCs were analyzed in primary cell
cultures from peripheral blood obtained from healthy subjects.
Informed consent was obtained from all subjects included in the
study and the local ethics committee approved all study methods.
At the time of blood sampling, all healthy subjects were without
any signs of infection, inflammation, or respiratory symptoms.
Candida Species and Culture Conditions
Candida albicans, C. krusei, C. glabrata, C. dubliniensis, and
C. parapsilosis strains were stored as frozen stocks in 35% glycerol
at −80◦C and routinely grown on Sabouraud (Sab) agar (1%
mycological peptone, 4% glucose, and 1.5% agar) and YPD
agar (1% yeast extract, 2% bacteriological peptone, 2% glucose,
and 1.5% agar) plates at 25◦C. One colony was inoculated and
shaken at 150 rpm at 30◦C in YPD broth (1% yeast extract,
2% bacteriological peptone, and 2% glucose) overnight. Cells
were harvested by centrifugation and washed twice in sterile
Dulbecco’s phosphate-buffered saline (PBS). Cells were counted
in a haemocytometer and density was adjusted to the desired
concentration in either PBS or RPMI 1640 medium. To generate
hyphae, live yeast forms of C. albicans were grown for 6 h at 37◦C
in RPMI 1640 medium (Gibco-BRL). Heat-inactivated Candida
cells were prepared by heat treatment of the cell suspension at
90◦C for 30 min.
In vitro MDSC Generation and Flow
Cytometry
Human MDSCs were generated in vitro as described previously
(Lechner et al., 2010; Rieber et al., 2015). In brief, isolated human
PBMCs were cultured in 24 well flat-bottom plates (Corning)
or 25 cm2 flasks (Greiner Bio-One) at 5 × 105 cells/ml in
RPMI 1640 supplemented with 10% heat-inactivated FCS (PAA
Laboratories), 2 mM glutamine (Sigma-Aldrich), 100 IU/ml
penicillin, and 100 mg/ml streptomycin (Biochrom; referred to
as “complete medium”) for 6 days, and GM-CSF (10 ng/ml,
Genzyme), heat-inactivated C. albicans, C. glabrata, C. krusei,
C. dubliniensis, and C. parapsilosis were added at a ratio of
1:5 (Fungi:PBMC) as indicated in figures. Dectin-1 antagonist
Laminarin obtained from Laminaria digitata (100 µg/ml, Sigma)
and Dectin-2 antagonist whole mannan particle preparation
isolated from Saccharomyces cerevisiae (100 µg/ml, Sigma) were
added in cell culture where indicated. For ROS inhibition assays,
PBMCs were incubated with NADPH oxidase inhibitor DPI
(DPI, 0.1 µM; Sigma-Aldrich) for 1 h prior to adding the
stimulants.
The number of MDSCs in % of all cells in medium only
cultures was set to 1-fold for every single experiment. The
MDSC induction due to the specific stimuli is presented as x-fold
compared to medium control. Medium and supplements were
refreshed on day 4 and supernatants were frozen for ELISA.
After 6 days, all cells were collected from PBMC cultures using
non-protease cell detachment solution Detachin (Genlantis).
G-MDSCs were characterized as CD33+CD11b+ CD14− cells as
described before (Rieber et al., 2013, 2015).
Cell Isolation and T-Cell Suppression
Assays
For functional assays, CD33+ MDSCs were isolated from
in vitro cultures using anti-CD33 magnetic microbeads and
autoMACS R©Pro Separator (Miltenyi Biotec) according to
manufacturer’s instructions. Morphology of the MDSCs was
analyzed by cytospin staining. For cytospin stainings 5 x 104
CD33+ cells were centrifuged in a Cytospin three centrifuge
(Shandon) at 800 rpm for 15 min followed by staining
with May-Grunwald-Giemsa method (Supplementary Figure
S1). T-cell suppression assays were performed as described
previously (Rieber et al., 2015). PBMCs were obtained from
healthy volunteers and stained with CFSE according to the
manufacturer’s protocol (Invitrogen). PBMCs were stimulated
with 100 U/ml IL-2 (R&D Systems) and 1 µg/ml OKT3 (Janssen
Cilag). Cell number was adjusted to 5 × 105 cells per ml and
a total of 60,000 PBMCs per well were seeded in RPMI1640
(Biochrom) medium, in a 96-well microtitre plate and different
numbers of MDSCs in RPMI1640 were added to get an MDSC:T-
cell ratio 1:2, 1;4, 1:8, 1:16, and 1:32. The cell culture was
supplemented with 10% heat-inactivated human serum, 2 mM
glutamine, 100 IU/ml penicillin, and 100 mg/ml streptomycin.
After 96 h of incubation in a humidified atmosphere at 37◦C
and 5% CO2, cells were harvested and supernatants were frozen
in −20◦C. CFSE-fluorescence intensity was analyzed by flow
cytometry to determine T-cell proliferation.
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Flow Cytometry
Antibodies against human CD4, CD8, and CD14 were purchased
from BD Pharmingen. Antibodies against CD11b and CD33
were purchased from Miltenyi Biotec. Flow cytometry was
performed using a FACSCalibur (BD). Results were expressed as
percent of positive cells and mean fluorescence intensity (MFI).
Calculations were performed with BD CellQuest Pro analysis
software and FlowJo.
Cytokine Analysis in Culture
Supernatants
IL-1β (R&D systems) and GM-CSF (Biolegend) ELISA Kits
were used to quantify cytokine protein levels in cell culture
supernatants. Released IFN-γ protein was quantified by using
the Human IFN-γ DuoSet (R&D Systems). All assays were
performed according to the manufacturer’s recommendations.
Statistical Analysis
Statistical analysis was performed in GraphPad Prism version 6.0
using a one-sample t-test. In all tests, differences were considered
significant at P < 0.05 (∗P < 0.05; ∗∗P < 0.01; ∗∗∗P < 0.001;
∗∗∗∗P < 0.0001).
RESULTS
Different Candida Species Induce
Functional G-MDSCs
First, we assessed the ability of NAC species to induce human
G-MDSCs and to control their function. G-MDSCs were
defined by their surface markers (CD11b+CD33+CD14−) and
by their characteristic to suppress T-cell responses. By comparing
Candida species, we found a differential pattern of MDSC
induction among all Candida species. While C. albicans (9.1-
fold) was the strongest inducer of G-MDSCs, C. krusei, and
C. glabrata (5.5- and 6.1-fold, respectively) also induced high
amounts of MDSCs, followed by C. parapsilosis (3.5-fold) and
C. dubliniensis (2.1-fold), which was least potent in comparison
to others (Figure 1A). G-MDSC induction by C. albicans was
observed for different fungal morphotypes and even occurred
using filter sterilized C. albicans yeast supernatants (Figure 1B).
M-MDSCs (CD11b+CD33+CD14+) were not induced during
these culture conditions. (Supplementary Figure S2).
MDSCs Induced by Non-albicans
Candida Species Are More Suppressive
than MDSCs Induced by C. albicans
The key function attributed to MDSCs is to suppress T-cell
responses. (Bronte et al., 2016). Therefore, we performed
functional assays to screen for T-cell suppression capability
of Candida-induced MDSCs. CFSE assays showed that NAS-
induced myeloid cells strongly suppressed both CD4+ and CD8+
T cell proliferation in a dose-dependent manner. Interestingly,
MDSCs induced by C. krusei and C. glabrata exhibited an even
higher suppressive activity than MDSCs induced by C. albicans,
an effect which was significant at MDSC:T cell ratios of 1:8 and
1:16. (Figures 2A,B). Apart from T-cell proliferation assays, we
also investigated the impact of fungi-derived MDSCs on IL-2
and OKT3-induced T cell cytokine production. These studies
demonstrated that MDSCs efficiently suppressed IFN-γ secretion
(Figure 2C).
Dectin-1, but not Dectin-2, Is Involved in
MDSC Induction by Non-albicans
Candida Species
In our previous work we showed that Dectin-1 plays a key role
in C. albicans-induced MDSC generation. Several studies also
reveal the role of Dectin-1 and also Dectin-2 (Saijo and Iwakura,
2011) in immune mechanisms against NAC species. We therefore
focussed on Dectin-1 and Dectin-2 as β-glucan and mannan
receptors, essentially involved in recognition of fungi. As shown
for C. albicans, blocking of Dectin-1 prior to co-culture with
fungal cells diminished the MDSC-inducing effect significantly
in C. glabrata. For C. krusei-induced MDSCs we observed a
similar, however, not significant effect. On the other hand,
blocking of Dectin-2 had no effect (Figure 3A) suggesting that
Dectin-2 is dispensable for Candida-mediated MDSC generation.
Since fundamental differences have been reported between host
recognition of C. albicans morphotypes (Lowman et al., 2014),
we next examined the impact of Dectin-1 blockage on MDSC
generation. In case of C. albicans yeast cells and hyphae, Dectin-
1 blockage significantly inhibited the MDSCs. Dectin-1 blockage
also led to a similar trend for filter sterilized C. albicans yeast cell
supernatant, however, it was not significant (Figure 3B).
Candida-Mediated MDSC Generation Is
Associated with GM-CSF, IL-1β, and ROS
Production
The cytokine GM-CSF has been involved in MDSC generation
(Gabrilovich and Nagaraj, 2009; Dolcetti et al., 2010) and
previous studies showed that GM-CSF is secreted upon
stimulation with fungal pathogens. (Li and Dongari-Bagtzoglou,
2009; Svobodová et al., 2012). Therefore we hypothesized
that GM-CSF might play a role in Candida-mediated MDSC
generation and analyzed the amount of GM-CSF in conditioned
medium obtained from PBMC-Candida co-culture. Our results
demonstrate that C. albicans stimulation leads to a high amount
of GM-CSF release in comparison to C. glabrata and C. krusei
(Figure 4A). In addition to GM-CSF, the inflammasome product
IL-1β has been previously involved in MDSC induction (Elkabets
et al., 2010; Lechner et al., 2011; Ballbach et al., 2016).
Hence, we quantified IL-1β protein in our assays and found
that C. albicans, C. glabrata, and C. krusei, all three major
pathogenic Candida species lead to high amounts of IL-1β
secretion upon PBMC stimulation (Figure 4B). These results
indicate that the two MDSC-related cytokines GM-CSF and
IL-1β seem to be associated with fungal MDSC induction.
ROS have been consistently involved in MDSC generation
and function (Gabrilovich and Nagaraj, 2009). To check the
role of ROS, MDSCs were generated in vitro by incubating
isolated PBMCs (5 × 105 cells/ml) with different Candida
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FIGURE 1 | In vitro MDSC generation by different Candida non-albicans species and C. albicans morphotypes. MDSCs were generated by incubating
freshly isolated PBMCs (5 × 105/ml) from healthy donors with medium only (negative control) or indicated stimulants. (A) PBMCs were cultured with heat killed yeast
cells of C. albicans, C. glabrata, C. krusei, C. parapsilosis, and C. dubliniensis (1 × 105/ml) for 6 days (n = 11–20) or (B) with heat killed C. albicans yeast cells
(1 × 105/ml), filter sterilized C. albicans yeast supernatant (5% SNT), or C. albicans hyphae (1 × 105/ml) for 6 days (n = 8–13). Granulocytic MDSCs
(CD11b+CD33+CD14−) were quantified by using Flow Cytometry. The number of MDSCs in % of all cells in medium only cultures was set to 1-fold for every single
experiment. The MDSC induction due to specific stimuli is presented as x-fold compared to medium control (mean ± SEM) and differences compared to controls
were analyzed by a one-sample t-test. Significant differences between control and G-MDSCs induction by stimulants are indicated by an asterisk (∗P < 0.05;
∗∗P < 0.01; ∗∗∗P < 0.001; ∗∗∗∗P < 0.0001).
FIGURE 2 | Candida-induced MDSCs suppress T cell responses. MDSCs generated by Candida species are able to suppress T-cell proliferation and function
in a dose dependent manner. The suppressive effects of CD33+-MACS-isolated MDSCs on CD4+ (green) and CD8+ (lilac) were assessed by T-cell proliferation
(CFSE polyclonal proliferation) assay. MDSCs were generated by incubating PBMCs (5 × 105/ml) from healthy donors with heat killed yeast cells of various Candida
species (1 × 105/ml) or C. albicans yeasts for 6 days. (A) Representative CFSE stainings, showing the effect of in vitro C. albicans, C. krusei, and C. glabrata
induced MDSCs on CD4+ and CD8+ T-cell proliferation. Different MDSC to T cell ratios were assessed by using a wide range of MDSC:Target ratio (1:2, 1:4, 1:6,
1:8, and 1:16). (B) The bar graphs represent the proliferation index compared to control conditions. Even at a higher MDSC:target ratio of 1:16, MDSCs induced by
C. krusei, and C. glabrata show higher suppressive activity in comparison to C. albicans. Data is shown as mean ± SEM (n = 4) ∗∗P < 0.01. (C) IFNγ secretion of T
cells is decreased by MDSCs. IFNγ secretion in the supernatant was measured on day 4 of MDSC/T cell co-culture experiments by ELISA. The concentration is
given in pg/ml (n = 3).
stimulants (1 × 105 cells/ml) and pretreatment for 1 h with
the NADPH oxidase inhibitor DPI (0.1 µM) where indicated.
These experiments showed that ROS contributed substantially to
fungi-mediated MDSC induction in vitro (Figure 4C).
DISCUSSION
Previous studies from our group demonstrated that pathogenic
fungi A. fumigatus and C. albicans induce MDSCs, which
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FIGURE 3 | Dectin-1 is involved in Candida-mediated MDSC induction in vitro. MDSCs were generated in vitro by incubating isolated PBMCs
(5 × 105 cells/ml) with stimulants and inhibitors. (A) with heat killed yeast cells of C. albicans, C. krusei, and C. glabrata (all 1 × 105/ml), (n = 8–11) or (B) with heat
killed C. albicans yeast cells (1 × 105/ml), filter sterilized C. albicans yeast cell supernatant (5% SNT) or C. albicans hyphae for 6 days (n = 8–13). Where indicated,
prior to stimulation, PBMCs were pretreated for 60 min with Dectin-1 inhibitor Laminarin (100 µg/ml) or Mannan (100 µg/ml) from Saccharomyces cerevisea to
mimic Dectin-2 binding without receptor activating capacity. (∗P < 0.05, Bars represent SEM).
FIGURE 4 | Candida-mediated MDSC generation involves GM-CSF, IL-1β, and ROS. GM-CSF, IL-1β, and ROS are involved in Candida-mediated MDSC
generation. Freshly isolated PBMCs (5 × 105 cells/ml) were cultured in medium only, or with heat killed yeast cells of C. albicans (1 × 105/ml), C. krusei
(1 × 105 cells/ml), and C. glabrata (1 × 105 cells/ml) for 4 days. For quantification of cytokines, co-culture supernatants were collected on day 4. (A) GM-CSF
(n = 8) and (B) IL-1β (n = 6) levels were quantified by ELISA. (C) MDSCs were generated in vitro by incubating isolated PBMCs (5 × 105 cells/ml) with with heat
killed yeast cells of C. albicans (1 × 105/ml), C. krusei (1 × 105 cells/ml), and C. glabrata (1 × 105 cells/ml) for 6 days. Prior to stimulation, PBMCs were pretreated
for 60 min where indicated with the NADPH oxidase inhibitor DPI (0.1 µM; n = 6) (∗P < 0.05, Bars represent SEM).
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suppress T cell responses (Rieber et al., 2015). In this study, we
compared the capacity of C. albicans, C. glabrata, C. krusei, and
C. parapsilosis to induce G-MDSCs and the relative strength of
Candida-induced G-MDSCs to suppress T-cell proliferation and
cytokine production.
Candida species are found as commensal organisms at
mucosal surfaces in the human body. Since C. albicans is the
most prominent fungus isolated from clinical samples, research
related to anti-fungal immune response is largely centered on
it. However, recent clinical studies have reported a rise in the
NAC species isolated from clinical samples of fungal infections.
NAC species associated with disease mainly include C. glabrata,
C. krusei, C. dubliniensis, and C. parapsilosis (Butler et al.,
2009). Here we extend our previous findings by showing that
the strength of Candida-mediated MDSC induction substantially
depends on the Candida species. While C. albicans was the
strongest inducer of MDSCs, C. dubliniensis showed the lowest
capacity. Importantly, our studies further show that not only
the extent, but also the functionality of MDSCs is regulated by
distinct Candida species. Collectively, these studies add to our
understanding of how different Candida species differentially
modulate host immunity.
Candida species consist of a diverse range of virulence factors
and morphotypes. Although limited in number, studies using
in vitro methods and in vivo infection strategies demonstrate that
host innate immune responses to Candida challenge including
activation and function of neutrophils (Dementhon et al.,
2012; Svobodová et al., 2012; Duggan et al., 2015), dendritic
cells (Bourgeois et al., 2011), and macrophages (Seider et al.,
2011) differ depending on the Candida species. In addition to
different species, we also used C. albicans yeast and hyphal
forms and filter sterilized supernatant from yeast cultures to
study the impact of different fungal morphotypes and soluble
products during fungi-mediated MDSC generation. C. albicans
yeast to hyphae morphogenesis has been attributed as a crucial
virulence factor during fungal pathogenesis. Various studies
demonstrate that immune cell recognition and subsequent
immune response toward different morphotypes of C. albicans
differs (Lewis et al., 2012; Lowman et al., 2014) due to differential
exposure of cell wall components, e.g., β-glucans (Wheeler
et al., 2008; Gow et al., 2011). However, in our studies, we
did not find a difference in MDSC induction after stimulation
with C. albicans yeast and hyphae (Rieber et al., 2015) or
supernatants. Further studies involving various morphotypes of
different NAC species and secreted fungal virulence factors will
help to dissect the mechanism underlying Candida-mediated
MDSC generation and function. T cells are pivotal immune cells
during C. albicans infection and patients with decreased CD4+
T cells were found to be highly susceptible to mucocutaneous
and invasive Candidiasis (Fidel, 2011; Lionakis and Netea, 2013).
Interestingly, C. glabrata and C. krusei-generated MDSCs were
more suppressive on T cell proliferation than C. albicans-
generated MDSCs and this phenomenon was recapitulated in the
suppression of IFNγ release. There is some evidence suggesting
differential T-cell responses depending on the Candida species.
C. albicans and C. parapsilosis were found to induce different
T-cell responses and cytokines. Human PBMCs stimulated with
heat killed C. parapsilosis yeast cells showed higher production
of IL-10 but lower amounts of IL-1β, IFNγ, IL-17, and IL-
22, when compared to cells stimulated with C. albicans (Tóth
et al., 2013). Another study reported distinct T-cell generation
in response to C. albicans and NAC species and T cells
generated after stimulation with C. albicans displayed cross-
reactivity only with C. tropicalis but not C. glabrata (Tramsen
et al., 2007). Our findings now also hint toward a species-
dependent innate immune response against different Candida
species. The induction of MDSCs might contribute to a fine-
tuned balance between pro-inflammatory effector and counter-
regulatory immune mechanisms, which has been demonstrated
to be crucial for an effective anti-fungal immune response
(Zelante et al., 2011, 2012; Rieber et al., 2015).
Candida albicans is recognized by different classes of PRRs
among which, the CLRs including Dectin-1and Dectin-2 are the
most important ones described so far. In our previous work, we
showed that dectin-1 mediated signaling was prominent in fungi-
induced MDSC generation. While Dectin-1 has been shown to be
the key PRR for C. albicans (Taylor et al., 2007; Marakalala et al.,
2013), Dectin-2 has emerged as a leading PRR to recognize both
C. albicans and C. glabrata (Saijo et al., 2010; Ifrim et al., 2014).
Therefore we focussed on these two PRRs to clarify their role
in Candida-mediated MDSC generation. In consistence with our
previous findings for C. albicans (Rieber et al., 2015), we found
that blockage of Dectin-1 but not Dectin-2 led to diminished
MDSC generation by C. albicans, C. glabrata, and C. krusei. Our
results demonstrate that Candida-mediated MDSC induction is
dependent on the type of Candida species, which is in line
with the notion that anti-fungal immune responses are species-
and strain-specific and vary in terms of recognition by the host
immune system (Netea et al., 2010; Marakalala et al., 2013).
Future studies will be essential to expand the understanding
how differential adaptation of Candida strains plays a role in
MDSC generation. Different morphotypes of C. albicans induce
an altered immune response. It has been reported that C. albicans
yeast cells and hyphae are differentially recognized by Dectin-
1 and Dectin-2 during host-pathogen-interaction (Saijo et al.,
2010; Saijo and Iwakura, 2011). We observed a similar MDSC
induction independent of the C. albicans morphotype. Dectin-
1 blockage significantly inhibited the MDSC generation by
C. albicans yeast cells and hyphae, and led to a similar trend
for C. albicans supernatant. This hints toward the presence
of a soluble Dectin-1 ligand in C. albicans supernatant that
contributes to MDSC generation. Interestingly, while yeast
mannan particles have been described to impact not only Dectin-
2, but also other PRRs like MR, DC-SIGN, and Mincle (Netea
et al., 2015), we did not observe any effect of mannan treatment
on Candida-mediated MDSC generation in our studies.
To elucidate the mechanism of Candida-mediated MDSC
induction, we further focused on two key cytokines, GM-CSF
and IL-1β, both reported to play an important role in MDSC
generation and homeostasis (Elkabets et al., 2010; Lechner et al.,
2011; Gabrilovich et al., 2012; Bayne et al., 2016), as well as during
fungal pathogenesis (Svobodová et al., 2012; Netea et al., 2015).
Stimulation of PBMCs with C. albicans and NAC species led
to release of GM-CSF and IL-1β. C. albicans-mediated release
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of GM-CSF was significantly higher than that of C. glabrata,
possibly explaining the stronger induction of MDSCs upon
C. albicans stimulation. All three species C. albicans, C. glabrata,
and C. krusei released similar amounts of IL-1β upon PBMC
stimulation. Since Dectin-1 was found to be the key receptor
for Candida-mediated MDSC generation, and previous studies
demonstrated that ROS act downstream of Dectin-1 (Branzk
et al., 2014), and ROS have been shown to be involved in MDSC
homeostasis (Corzo et al., 2010; Gabrilovich et al., 2012), we
further examined the role of ROS for Candida-mediated MDSC
induction. These studies demonstrated that ROS contributed
substantially to NAC-mediated MDSC induction in vitro.
CONCLUSION
Our results demonstrate that Candida-mediated MDSC
induction is differentially regulated at the species level and
differentially affects effector T-cell responses. In our previous
study using a systemic infection mouse model for C. albicans, we
showed that adaptive transfer with MDSCs leads to a protective
effect against invasive Candidiasis. While the classical MDSC
inducing factor GM-CSF has already been proposed as one of the
leading candidates for anti-fungal adjunctive therapy (Vazquez
et al., 1998; van de Veerdonk et al., 2012), in vivo generation of
MDSCs or ex vivo expansion and adoptive transfer might become
an interesting approach for future therapeutic strategies against
infections caused by Candida species.
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Supplementary Figure S1 
FACS gating and photomicrograph showing granulocytic 
morphology of in vitro Candida-induced  MDSCs: 
MDSCs were generated in vitro by incubating isolated 
PBMCs (5x105 cells/ml) with GM-CSF, heat killed yeast 
cells of C. albicans, C. krusei and C. glabrata (all 1x105/ml) 
for 6 days. Phenotyping was done by selecting 
CD33+CD14- cells. 
For microscopy, CD33+ MDSCs were MACS-isolated after 6 
days culture and cytospins were stained with May–
Gruenwald–Giemsa. Pictures were obtained by using a 
reverted Zeiss Axiovision Microscope mounted with a 
Canon 550D camera. Cells with a granulocytic-MDSC 
morphology are marked with red arrow. 
A. B.
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 CF Lung Disease 
 Cystic fibrosis (CF) lung disease, the most common 
inherited lethal disease in Caucasians  [1] , is characterized 
by an early  [2] , nonresolving  [3] and harmful  [3, 4] acti-
vation of the innate immune system. CF is caused by mu-
tations in the CF transmembrane conductance regulator 
 (CFTR) gene, mainly expressed at the apical membrane 
of epithelial cells  [5] . However, besides  CFTR , other genes 
(‘modifier genes’) also appear to play a significant role in 
modulating lung disease severity and immune response 
 [6–9] , particularly genetic variants of transforming 
growth factor β1 (TGF-β1)  [10–12] , mannose-binding 
lectin (MBL2)  [13] and interferon-related developmental 
regulator 1 (IFRD1)  [14, 15] . Exome sequencing has re-
vealed that the variants in dynactin protein, DCTN4, are 
linked with the chronic infections in CF  [16] . A more re-
cent meta-analysis  [17] has identified 5 loci:  MUC4/
MUC20 ,  SLC9A3 ,  HLA Class II and  AGTR2/SLC6A14 to 
be associated with the lung function in CF. Labenski et al. 
 [18]  have reported 2 cytokine receptor genes,  INFGR1 
and  IL1B , and a transcription factor, STAT3, which is as-
sociated with the basic  CFTR defect as candidate modi-
 Key Words 
 Cystic fibrosis · Lung disease · Host defense · Immune 
response  · Neutrophils · Pattern recognition receptors · 
Toll-like receptor  
 Abstract 
 Cystic fibrosis (CF) lung disease is characterized by chronic 
infection and inflammation. The inflammatory response in 
CF is dominated by the activation of the innate immune sys-
tem. Bacteria and fungi represent the key pathogens chron-
ically colonizing the CF airways. In response, innate immune 
pattern recognition receptors, expressed by airway epithe-
lial and myeloid cells, sense the microbial threat and release 
chemoattractants to recruit large numbers of neutrophils 
into CF airways. However, neutrophils fail to efficiently clear 
the invading pathogens, but instead release harmful prote-
ases and oxidants and finally cause tissue injury. Here, we 
summarize and discuss current concepts and controversies 
in the field of innate immunity in CF lung disease, facing the 
ongoing questions of whether inflammation is good or bad 
in CF and how innate immune mechanisms could be har-
nessed therapeutically.  © 2016 S. Karger AG, Basel 
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fier genes in a study comparing F508del homozygous CF 
patient subsets. Some lesser-known genetic variations 
linked to CF lung disease are  EDNRA  [19] ,  IL-8  [20] and 
 SERPINA1  [9] .
 Studies from regions with CF newborn screening indi-
cate that the innate immune system, as reflected proto-
typically by neutrophil products present in CF airway flu-
ids, is operative in infants with CF and predicts the later 
outcome of irreversible pulmonary disease  [2] . Based on 
these and other studies, innate immune cells have come 
into the focus of understanding and treating CF lung dis-
ease  [3] . Whilst there are several studies supporting the 
notion that unopposed neutrophil products, such as ex-
tracellular elastase, are detrimental for tissue integrity 
and innate immune cell receptors  [3, 21] and can be used 
as noninvasive biomarkers for CF airway inflammation 
 [22, 23] , therapeutic approaches to dampen excessive 
neutrophilic inflammation in CF lung disease have re-
mained largely unsuccessful  [24] . Neutralizing neutro-
phil elastase (NE) by using antiproteases showed some 
effects in preclinical and clinical studies; however, the 
benefits for lung function are so far not convincing  [25] . 
Interfering with neutrophil recruitment through CXCR2 
antagonists was safe and showed anti-inflammatory po-
tential, yet no beneficial effects on lung function were 
found  [26] . As CF airways are chronically colonized with 
bacteria and fungi  [27] , completely abrogating neutrophil 
recruitment into the lung bears the inherent risk of un-
leashing bacterial and fungal infections. Collectively, in-
nate immune pathways are activated early in CF and seem 
to cause more harm than good within the pulmonary mi-
croenvironment; however, the therapeutic implications 
of these insights remain a matter of debate. To dissect the 
innate immune response in CF and develop future phar-
macotherapeutic strategies, we have composed this re-
view, embedded in a thematic CF series in the  Journal of 
Innate Immunity . 
 Current Controversies in Innate Immunity of CF Lung 
Disease 
 Innate immunity comprises both cellular and humor-
al factors. Here, we focus on the cellular components of 
innate immunity and their pathogenic, diagnostic and/or 
potentially therapeutic role in CF lung disease. However, 
before considering innate immune cells as pharmaco-
therapeutic targets, one must understand their activation 
and effector functionalities. Therefore, we start with sum-
marizing and discussing the mechanisms by which innate 
immune cells sense and are activated by CF pathogens. 
Based on this, we focus on the role of neutrophils, prob-
ably the key type of innate immune cell in CF lung dis-
ease, including their distinct innate immune receptor 
profiles and phenotypes in the proinflammatory CF air-
way microenvironment. Overall, our review should stir a 
discussion of the following controversies in the field:
 • Is inflammation good or bad in CF lung disease? The 
correlation between neutrophil activation and irre-
versible lung tissue remodeling (bronchiectasis)  [2] 
suggests a harmful role, but without functional neu-
trophils (as exemplified in patients with the primary 
immunodeficiency chronic granulomatous disease), 
we cannot efficiently defend against bacteria and fun-
gi. Consequently, dampening neutrophil activation 
would be reasonable, while completely abrogating 
neutrophil influx or function might be dangerous. 
 • How does harmful proinflammatory neutrophil acti-
vation in CF get dampened? Harmful unopposed neu-
trophil functions, such as unopposed protease release 
and neutrophil extracellular trap (NET) formation 
should be controlled, but how? Antiproteases show 
limited success so far, but studies are ongoing. NET 
formation still represents a controversial area  [28] . On 
the one hand, NETs can entrap pathogens and may 
therefore act beneficially. On the other hand, abun-
dant NETs, as found in CF airways, can obstruct the 
airway lumen and correlate with decreased lung func-
tion in CF patients  [29] . Recombinant DNase (Dor-
nase alfa) is clinically effective in CF patients by cleav-
ing DNA strands and facilitating airway mucus clear-
ance  [30] . A recent study suggested that the majority 
of extracellular DNA in CF airways is derived from 
NETs  [31] . Thus, the clinical effectiveness of recombi-
nant DNase might support the concept that the preva-
lence of NETs causes more harm than good in CF lung 
disease. However, DNases cleave extracellular DNA 
and do not prevent de novo NET generation or release. 
Approaches how to target NET generation may in-
volve interfering with reactive oxygen species (ROS) 
or MAPK, which have been found important for NET 
formation  [32, 33] . Studies comparing the effect of in-
hibiting intracellular NET generation versus cleaving 
free extracellular DNA strands would shed more light 
on the kinetics and dynamics of NET-pathogen inter-
actions in lung disease and beyond. Alternatively, spe-
cific neutrophil phenotypes, such as olfactomedin-4- 
or CD177-expressing neutrophil subsets, could be tar-
geted  [28] . Their functional role and CF disease 
relevance remains to be defined.  
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 • When should inflammation be targeted? At first 
glance, the earlier, the better, in order to prevent in-
flammation-associated tissue damage and avoid irre-
versible pulmonary tissue remodeling as soon as pos-
sible in the course of disease. On the other hand, neu-
trophils could be essential in early host-pathogen 
interactions by restricting airway pathogen coloniza-
tion in the first years of life, when the airways are in-
tensively exposed to environmental microbes and vac-
cinations are performed. Further investigations into 
CF lung disease are required to define the time win-
dows when inflammation could be targeted safely 
without significantly impairing the protective innate 
immune defenses.  
 Innate Immune Activation in CF Lung Disease 
 Sensitive microbial detection mechanisms as well as 
tailored immune responses are required to efficiently 
protect the host from pathogens. Simultaneously, inflam-
mation has to be tightly controlled and limited to avoid 
overshooting immune responses and collateral tissue in-
jury. In 1989, Janeway  [34]  proposed the pattern recogni-
tion theory, stating that the microbial presence is sensed 
by the host innate immune system through the detection 
of distinct molecular structures called pathogen-associat-
ed molecular patterns (PAMPs) that are expressed by the 
pathogen but are absent in the host. To sense the presence 
of microorganism, the cells of the immune system possess 
germline-encoded pattern recognition receptors (PRRs) 
with 4 different families having been currently identified. 
These families include transmembrane proteins such as 
Toll-like receptors (TLRs) and C-type lectin receptors 
(CLRs) as well as cytoplasmic proteins such as the reti-
noic acid-inducible gene  (RIG) -I-like receptors (RLRs) 
and NOD-like receptors (NLRs). Apart from PAMPs, 
PRRs also recognize host-derived patterns/molecules, 
termed damage- or danger-associated molecular patterns 
(DAMPs).
 CF lung disease is mainly characterized by bacterial 
and fungal colonization and infection. Therefore, in the 
sections below, we will focus on these 2 microbial entities 
and the corresponding innate immune responses. 
 Bacterial Recognition: TLRs 
 The main bacteria commonly identified in CF lungs 
in early disease/infancy are  Staphylococcus aureus and 
 Haemophilus influenzae , followed in adolescence and 
adulthood by the major CF pathogen  Pseudomonas ae-
ruginosa . However, beyond these ‘classical’ CF bacteria, 
microbiome studies indicate that a much broader variety 
of bacterial species, including anaerobes, colonize CF air-
ways  [35–37] . TLRs are the main innate immune recep-
tors (PRRs) to sense bacteria. Ten and 12 TLRs have been 
identified in humans and mice, respectively, and TLR1–
9 are conserved in both species  [38] . The PRRs respon-
sible for the recognition of  P. aeruginosa in CF lung dis-
ease are TLRs, Asialo-GM1 receptors  [39] and the 
NLRC4/IPAF inflammasome  [40] . TLR2, TLR4, TLR5 
and/or TLR9 have been reported to sense  P. aeruginosa 
 [41] . The bacteria-derived ligands known to bind TLR2 
are lipoproteins, components of the extracellular capsule 
and secreted toxin, ExoS, with C-terminal-specific inter-
action  [42–44] . Reports have shown a role for TLR2 in 
the recognition of mannuronic acid polymer, a major 
component of the alginate capsule and slime GLP, pro-
duced by mucoid and nonmucoid strains of  P. aerugi-
nosa  [45, 46] . Lipopolysaccharide (LPS) is mainly sensed 
through TLR4 and, after recognition, the TLR4/LPS 
complex is rapidly endocytosed and trafficked for lyso-
somal degradation in order to terminate further inflam-
matory cascades  [47] . The lipid A component of LPS li-
gates TLR4, inducing a potent immune response  [48] , 
with the hexacyclated form being a strong activator of 
TLR4-mediated signaling in humans  [49] . Hexacylated 
lipid A is often produced by bacterial strains adapted to 
the chronic CF microenvironment  [50, 51] , leading to 
escape from the host antimicrobial peptides and in-
creased recognition by human TLR4. In contrast to this 
structural peculiarity, a recent study by Di Lorenzo et al. 
 [52] sheds new light on the activation mechanism of 
TLR4/MD2 complex by penta-acylated lipid A produced 
by the CF isolates of  Burkholderia cenocepacia. TLR5 
specifically binds to flagellin, a primary constituent of 
flagella important for microbial motility  [53] . However, 
the correlation between bacterial motility and immune 
evasion by  P. aeruginosa remains controversial  [54] . An 
in vivo study highlighted the proinflammatory role of 
flagellin-mediated TLR5 activation  [55] . Descamps et al. 
 [56] reported that TLR5, rather than TLR4, is essential 
for bacterial phagocytosis and killing by murine alveolar 
macrophages (AMs) in vitro and in vivo. The authors 
also demonstrated that nonflagellated  P. aeruginosa or 
mutants defective in TLR5 activation are resistant to AM 
clearing, which is dependent on TLR5 signaling and IL-
1β production. The intracellular function of TLR9 is 
characterized by detection of unmethylated CpG motifs 
in bacterial DNA  [57, 58] . Synergistic effects of TLR2, 
TLR6 and TLR9 have been reported using in vivo studies 
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 [59] . Further studies report a resistant phenotype of 
TLR9 –/– mice to  P. aeruginosa infection compared to 
wild-type mice  [60] . These unexpected findings are at-
tributed to increased airways cytokine production lead-
ing to effective bacterial clearance in the lungs of the 
TLR9 –/– mice. 
 The NLRC4 and NLRP3 Inflammasomes 
 NLRs are cytosolic proteins that respond to a variety 
of ligands, from bacterial and viral components to par-
ticulate matter and crystals. The mammalian NLR fam-
ily comprises >20 members, containing a C-terminal leu-
cine-rich repeat domain, a central nucleotide-binding 
NACHT domain and an N-terminal protein-protein in-
teraction domain composed of a caspase activation and 
recruitment domain (CARD) or Pyrin domain  [61–63] . 
The transmembrane secretion systems of intracellular 
pathogens or bacteria serve as cytosolic microbe-associ-
ated molecular patterns (MAMPs) that may interact with 
NLRs  [64–66] . Regarding human pulmonary pathogens, 
NLRC4 and NLRP3 are the 2 most widely studied NLRs 
that orchestrate immune responses  [67–69] . In addition 
to TLR5, bacterial flagellin is sensed by NLRC4  [70, 71] . 
Sutterwala et al.  [40] have further described that NLRC4 
triggers the activation of the inflammasome upon infec-
tion with  P. aeruginosa , resulting  in macrophage cell 
death and the secretion of the proinflammatory cyto-
kines, IL-1β and IL-18. This activation cascade was 
shown to be IPAF-dependent, but flagellin-independent. 
Moreover, in vivo studies revealed an increased suscep-
tibility of NLRC4-deficient mice against  P. aeruginosa 
infection  [72] . In addition to  Pseudomonas , other Gram-
negative bacteria, such as  Salmonella ,  Legionella and  Shi-
gella , have also been found to activate the NLRC4 inflam-
masome  [73–75] . In a recent study, the role of NLRP3 
inflammasome activation in the CF lung has been de-
scribed in association with elevated levels of ceramide 
 [76] . The authors demonstrated an upregulation and re-
cruitment of the adapter protein apoptosis-associated 
speck-like protein (ASC) and caspase-1 in the lungs of 
CF mice. The activation of NLRP3 is characterized by a 
canonical two-step deubiquitination mechanism that is 
initiated by priming through TLR signaling (e.g. TLR4), 
inducing NF-κB-dependent NLRP3 protein synthesis, 
followed by a second signal leading to full NLRP3 inflam-
masome assembly  [77] . In CF airway epithelial cells,  P. 
aeruginosa infection has been shown to trigger mito-
chondrial dysfunction and enhance mitochondrial Ca 2+ 
uptake, leading to NLRP3 inflammasome activation  [78, 
79] . 
 Fungal Recognition 
 With constant inhalation of fungal spores, the human 
airway immune system has evolved a plethora of fine-
tuned defense mechanisms for effective fungal clearance, 
involving, mainly, AM, neutrophils and antimicrobial 
peptides  [80–85] . With ageing and more intensified an-
tibiotic treatments, prevalence rates of fungal coloniza-
tion increase in CF lung disease, traditionally known to 
be mainly colonized by a bacterial community  [86–88] . 
The reported emerging rate of filamentous fungal spe-
cies, such as  Aspergillus fumigatus ,  in CF, is found to be 
most frequent; however, other important filamentous 
fungi including  Scedosporium sp. and  Exophiala derma-
tiditis have also been identified  [89, 90] . The sensitization 
of CF patients to the airway microenvironment presents 
a wide range of unresolved questions. However, previous 
reports have proposed a crucial role for dendritic cells 
and Th2-associated chemokines, like CCL17  [91] . Phago-
cytic cells play an essential role in protection against the 
fungal infections, and abrogation of these cells leads to 
increase susceptibility towards pathogens  [92] . The re-
ceptors involved in these processes include secreted fac-
tors such as pentraxin-3 (PTX3), C-type lectins, comple-
ment system and membrane PRRs such as TLRs  [93] . 
Previous reports have shown that  A. fumigatus conidia 
are recognized by TLRs  [94, 95] and β-glucan receptor 
dectin-1 on dendritic cells, AM and lung epithelial cells 
 [96, 97] . TLRs, in particular TLR2  [98, 99] , TLR4  [100, 
101] or an interplay between TLR2, 4 and 9 via an MyD88-
dependent pathway  [96] , are described as playing an im-
portant role in the host immune response to  A. fumiga-
tus . The endocytic PRR dectin-1 is crucial in the recogni-
tion and internalization of specific morphotypes of  A. 
fumigatus  in AM  [102, 103] , and a novel mechanism of 
dectin-1 induction in human bronchial epithelial cells 
and its consequences for innate immune responses 
against  A. fumigatus have been described by Sun et al. 
 [97] . Secreted receptor pentraxin PTX3 also plays an im-
portant role in the clearance of fungal burden in vivo af-
ter  A. fumigatus pulmonary infection. PTX3 levels in a 
CF patient’s respiratory secretions and sputum samples 
were found to have decreased  [104] ; this could be one of 
the explanations for recurrent lung infections in CF 
lungs. Another study showed that a serum opsonin, H-
ficolin, modulates host immune response by binding to 
 A. fumigatus  [105] . The authors further showed that fol-
lowing pathogen recognition, there is an enhanced acti-
vation of the lectin complement pathway and fungal as-
sociation with lung epithelial cells. 
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 Innate Immune Cells 
 Airway epithelial cells form the first line of defense 
against microbial infections and serve as a central player 
in the mucociliary clearance of the lung. The key innate 
immune functions of the epithelium include (1) secretion 
of a variety of antimicrobial substances, (2) release of che-
mokines, cytokines and growth factors that mediate leu-
kocyte recruitment, (3) modulation of adaptive immu-
nity and (4) tissue repair and remodeling  [3, 106, 107] . 
Direct interaction between the CFTR protein and patho-
gens has been previously suggested, where CFTR serves 
as a receptor for  Salmonella typhi  [108] and  P. aeruginosa 
 [109, 110] when expressed on intestinal or airway epithe-
lial cells, respectively. Moreover,  A. fumigatus spores are 
readily ingested by airway epithelial cells and the uptake 
and killing of conidia are both impaired in epithelial cells 
lacking CFTR  [111] . The bronchial epithelium has been 
previously shown to modulate its sensitivity towards mi-
crobial recognition by regulating receptor expression lev-
els  [112] . Upon pathogen recognition by specific PRRs, 
the activation of intracellular signaling cascades initiates 
proinflammatory and antimicrobial responses. Bacterial 
infection in CF can exacerbate lung inflammation by ex-
aggerating proinflammatory gene expression via TLR ac-
tivation in airway epithelial cells  [43] . In vitro  as  well as 
 in vivo studies have shown that excessive cytokine release 
upon  P. aeruginosa exposure to CF airway epithelial cells 
is mainly mediated by TLR5/flagellin or TLR4/LPS inter-
actions  [113, 114] . In particular, intracellular TLR4 traf-
ficking seems to be dysregulated and attenuated in hu-
man CF airway epithelial cells compared to non-CF cells 
 [115–117] . Hyperresponsiveness of primary airway epi-
thelial cells to LPS, despite expressing normal levels of 
TLR4, has been attributed to the reduced surface expres-
sion of coreceptor CD14 and lower levels of the costimu-
latory molecule MD2  [118] . Conflicting studies have been 
reported regarding the localization of TLR5 on airway 
epithelial cells, with apical dominance on human and 
murine cells  [119–122] and basolateral expression on po-
larized human nasal and bronchial epithelium  [123–125] . 
Specific cell source, modulation of culture conditions 
and/or specific stimuli might explain these discrepancies. 
A strong synergism between TLR2/PGN- and TLR4/LPS-
mediated IL-8 production and IL17A was found in hu-
man bronchial epithelial cell lines  [126] . Recently, geno-
typing of TLR polymorphisms revealed that CF airway 
epithelial cells are homozygous for TLR1 SNP 1602S and 
possess a diminished innate immune response towards 
 Mycobacterium abscessus  infection .  [127] . In a separate 
study, TLR SNPs were associated with CF lung function 
decline  [128] . A recent study  [129] demonstrated that  S. 
aureus filtrates inhibit  P. aeruginosa filtrate-mediated 
IL-8 production. 
 The CF airways are characterized by a neutrophil-rich 
environment. Neutrophils have been mainly implicated 
in controlling bacterial and fungal infections, but can also 
lead to airway damage upon activation through the re-
lease of enzymes (proteases) and oxidants  [28] . Neutro-
phils are the first cell type recruited to the CF airway com-
partment. The recruitment of blood neutrophils into the 
airway compartment is mainly regulated through chemo-
kines, such as IL-8, and lipid-mediators, such as LTB 4 . 
The efficient antibacterial function of neutrophils in the 
CF airway micromilieu is impeded due to several mecha-
nisms, such as proteolytic damage of airway neutrophils, 
neutrophil cell death and bacterial/fungal biofilm forma-
tion that prevents phagocytosis  [3] . At the site of infec-
tion, neutrophils sense PAMPs or DAMPs via PRRs. Ex-
pression and functionality of TLRs in neutrophils have 
been studied in the context of CF lung disease. Collec-
tively, TLR2, TLR4 and TLR5 are suggested to be most 
essential for neutrophil- P. aeruginosa interactions. CF 
airway neutrophils express remarkably high levels of 
TLR5, which correlates with lung function in CF patients 
 [130, 131] . In a separate study, TLR surface expression 
was investigated on circulating and induced sputum neu-
trophils in CF patients. Compared to healthy controls, 
decreased expression of TLR2 was detected on circulating 
neutrophils in CF patients  [132] . Furthermore, an inverse 
relationship between TNF-α serum levels and TLR2 sur-
face expression on circulating neutrophils has been de-
scribed  [130] . DAMPs such as proline-glycine-proline 
and high-mobility group box protein-1 (HMGB1) have 
been implicated in CF lung disease. A high concentration 
of these mediators is found in CF airways and they serve 
as neutrophil chemoattractants to drive lung inflamma-
tion  [133] . S100A12, a member of the S100/calgranulin 
family and a neutrophil-derived DAMP, was found in 
abundance in CF airway fluids leading to activation of 
downstream metabolic and stress pathways following 
neutrophil entry into CF airways  [134] .
 Novel Therapeutic Concepts 
 Despite a plethora of proinflammatory innate immune 
pathways having been studied and determined as playing 
a significant role in CF lung disease, therapeutic exploita-
tion of these pathomechanisms remains scarce. For a 
broader and more in-depth discussion of this aspect, we 
D
ow
nl
oa
de
d 
by
: 
46
.5
.1
8.
54
 - 
12
/2
2/
20
16
 5
:0
1:
30
 P
M
 Ralhan/Laval/Lelis/Ballbach/Grund/
Hector/Hartl
 
 J Innate Immun 2016;8:531–540 
DOI: 10.1159/000446840
536
refer to thematic review articles  [24, 135] . Ibuprofen rep-
resents a clinically available anti-inflammatory drug that 
has been shown to slow lung function decline in pediat-
ric/adolescent CF lung disease  [136–139] , but its broad 
clinical usage outside the USA is restricted by drug-mon-
itoring requirements. Correlations between lung func-
tion and inflammatory markers in CF airway fluids (neu-
trophil counts, IL-8 and NE) have been demonstrated in 
multicenter CF patient cohorts  [22] , suggesting that tar-
geting neutrophil-related products may be beneficial in 
CF lung disease. However, clinical studies aiming to neu-
tralize free NE activity in CF airways by the delivery of 
antiproteases, such as α-1 antitrypsin, showed modulated 
airway inflammation but failed to show convincing ef-
fects on lung function  [25] . In contrast, the use of the oral 
antioxidant  N -acetylcysteine, as a strategy to rebalance 
antioxidant deficiencies in CF, shows beneficial effects on 
lung function, but has no effect on neutrophilic inflam-
mation  [140] . Future studies are required to reconcile 
these findings and to further assess the therapeutic poten-
tial of antiprotease or antioxidant approaches in CF lung 
disease  [24, 141] . The antibiotic azithromycin is known 
to have anti-inflammatory effects. A clinical trial  [142] 
showed that azithromycin treatment reduced circulating 
neutrophil counts and systemic blood biomarkers, in-
cluding C-reactive protein, serum amyloid A and calpro-
tectin, and was correlated with the improvement in lung 
function and weight gain. Other anti-inflammatory ther-
apeutic approaches include sildenafil (phosphodiesterase 
inhibitor)  [143] , CXCR2 inhibition  [26] and others less-
advanced ones that are not discussed here. Collectively, 
therapeutic interventions to dampen inflammation in CF 
remain an appealing yet challenging approach. 
 Conclusions and Outlook 
 There is broad consensus about the concept that the 
innate immune system is activated early and strongly in 
CF lung disease, leading to the continuous recruitment of 
neutrophils into CF airways  [3] . These neutrophils re-
lease proteases that cause harm to the host by degradation 
 Fig. 1. Innate immune activation in CF airways. Due to continuous production of cytokines and chemokines, 
especially IL-8, neutrophils are recruited into the CF airways. Bacterial and fungal PAMPs and host-derived 
DAMPs further activate downstream signaling pathways through the activation of PRRs, and lead to enhanced 
cytokine and chemokine production. Infiltrated neutrophils release proteases and oxidants, resulting in perpetu-
ated inflammation and tissue injury. 
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of the pulmonary tissue and the immune receptors ( fig. 1 ). 
However, controversy exists as to whether the targeting 
of innate immune pathways, by neutrophil recruitment 
and/or activation, represents a promising strategy in CF 
lung disease. On the one hand, there are clear relation-
ships between neutrophil products, prototypical NE and 
decreased lung function  [22] as well as bronchiectasis  [2] . 
On the other hand, targeting excessive proteolytic activi-
ties in CF has clinically not been successful so far. Inter-
fering with neutrophil recruitment through CXCR2 inhi-
bition represents a causative anti-inflammatory approach 
 [26] , but has also not shown any clinical benefits for lung 
function. Novel strategies to dampen innate immunity in 
CF in the future could involve anti-inflammatory pro-
resolution lipid mediator pathways, such as resolvins 
 [144] , and the endocannabinoid system  [145] . However, 
most of these pathways have mainly been assessed in 
acute lung inflammation models and not in chronic CF 
lung disease. Both preclinical and clinical studies are war-
ranted to evaluate these and other anti-inflammatory 
mechanisms in the context of CF lung disease.
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